T.	NP	T.
A	NP	A
Call	NP	Call
to	TO	to
Action	NP	Action
to	TO	to
Develop	NP	<unknown>
Integrated	NP	Integrated
Curricula	NP	<unknown>
in	IN	in
Cardiorenal	NP	<unknown>
Medicine	NP	Medicine
.	SENT	.
A.	NP	A.
With	IN	with
the	DT	the
adoption	NN	adoption
of	IN	of
the	DT	the
new	JJ	new
definition	NN	definition
and	CC	and
classification	NN	classification
of	IN	of
cardiorenal	JJ	<unknown>
syndrome	NN	syndrome
(	(	(
CRS	NP	CRS
)	)	)
and	CC	and
its	PP$	its
relevant	JJ	relevant
subtypes	NNS	subtype
,	,	,
much	JJ	much
attention	NN	attention
has	VHZ	have
been	VBN	be
placed	VVN	place
on	IN	on
elucidating	VVG	elucidate
the	DT	the
mechanisms	NNS	mechanism
of	IN	of
heart	NN	heart
and	CC	and
kidney	NN	kidney
interactions	NNS	interaction
.	SENT	.
Of	IN	of
great	JJ	great
interest	NN	interest
are	VBP	be
the	DT	the
pathophysiological	JJ	<unknown>
pathways	NNS	pathway
by	IN	by
which	WDT	which
acute	JJ	acute
heart	NN	heart
failure	NN	failure
may	MD	may
result	VV	result
in	IN	in
acute	JJ	acute
kidney	NN	kidney
injury	NN	injury
(	(	(
AKI	NP	Aki
;	:	;
type	NN	type
1	CD	@card@
)	)	)
,	,	,
chronic	JJ	chronic
heart	NN	heart
failure	NN	failure
accelerating	VVG	accelerate
the	DT	the
progression	NN	progression
of	IN	of
chronic	JJ	chronic
kidney	NN	kidney
disease	NN	disease
(	(	(
CKD	NP	CKD
;	:	;
type	NN	type
2	CD	@card@
)	)	)
,	,	,
AKI	NP	Aki
provoking	JJ	provoking
cardiac	JJ	cardiac
events	NNS	event
(	(	(
type	NN	type
3	CD	@card@
)	)	)
,	,	,
and	CC	and
CKD	NP	CKD
increasing	VVG	increase
the	DT	the
risk	NN	risk
and	CC	and
severity	NN	severity
of	IN	of
cardiovascular	JJ	cardiovascular
disease	NN	disease
(	(	(
type	NN	type
4	CD	@card@
)	)	)
.	SENT	.
A	DT	a
remarkable	JJ	remarkable
interest	NN	interest
has	VHZ	have
also	RB	also
been	VBN	be
placed	VVN	place
on	IN	on
the	DT	the
acute	JJ	acute
and	CC	and
chronic	JJ	chronic
systemic	JJ	systemic
conditions	NNS	condition
,	,	,
such	JJ	such
as	IN	as
sepsis	NN	sepsis
and	CC	and
diabetes	NN	diabetes
,	,	,
which	WDT	which
simultaneously	RB	simultaneously
affect	VVP	affect
heart	NN	heart
and	CC	and
kidney	NN	kidney
function	NN	function
(	(	(
type	NN	type
5	CD	@card@
)	)	)
.	SENT	.
Furthermore	RB	furthermore
,	,	,
the	DT	the
physiology	NN	physiology
of	IN	of
acute	JJ	acute
and	CC	and
chronic	JJ	chronic
heart-kidney	NN	<unknown>
cross	NN	cross
talk	NN	talk
is	VBZ	be
drawing	VVG	draw
attention	NN	attention
to	TO	to
hemodynamics	NNS	<unknown>
(	(	(
fluids	NNS	fluid
,	,	,
pressures	NNS	pressure
,	,	,
flows	NNS	flow
,	,	,
resistances	NNS	resistance
,	,	,
perfusion	NN	perfusion
)	)	)
,	,	,
physiochemical	JJ	<unknown>
(	(	(
electrolytes	NNS	electrolyte
,	,	,
pH	NN	pH
,	,	,
and	CC	and
toxins	NNS	toxin
)	)	)
,	,	,
and	CC	and
biological	JJ	biological
(	(	(
inflammation	NN	inflammation
,	,	,
immune	JJ	immune
system	NN	system
activation	NN	activation
,	,	,
neurohormonal	JJ	<unknown>
signals	NNS	signal
)	)	)
processes	VVZ	process
.	SENT	.
Common	JJ	common
clinical	JJ	clinical
scenarios	NNS	scenario
call	VVP	call
for	IN	for
recognition	NN	recognition
,	,	,
knowledge	NN	knowledge
,	,	,
and	CC	and
skill	NN	skill
in	IN	in
managing	VVG	manage
CRS	NP	CRS
.	SENT	.
There	EX	there
is	VBZ	be
a	DT	a
clear	JJ	clear
need	NN	need
for	IN	for
medical	JJ	medical
and	CC	and
surgical	JJ	surgical
specialists	NNS	specialist
that	WDT	that
are	VBP	be
well	RB	well
versed	VVN	verse
in	IN	in
the	DT	the
pathophysiology	NN	<unknown>
and	CC	and
the	DT	the
clinical	JJ	clinical
manifestations	NNS	manifestation
that	WDT	that
arise	VVP	arise
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
CRS	NP	CRS
.	SENT	.
With	IN	with
this	DT	this
editorial	NN	editorial
,	,	,
we	PP	we
are	VBP	be
making	VVG	make
a	DT	a
call	NN	call
to	TO	to
action	NN	action
to	TO	to
stimulate	VV	stimulate
universities	NNS	university
,	,	,
medical	JJ	medical
schools	NNS	school
,	,	,
and	CC	and
teaching	VVG	teach
hospitals	NNS	hospital
to	TO	to
create	VV	create
a	DT	a
core	JJ	core
curriculum	NN	curriculum
for	IN	for
cardiorenal	JJ	<unknown>
medicine	NN	medicine
to	TO	to
better	RBR	well
equip	VV	equip
the	DT	the
physicians	NNS	physician
of	IN	of
the	DT	the
future	NN	future
for	IN	for
these	DT	these
common	JJ	common
,	,	,
serious	JJ	serious
,	,	,
and	CC	and
frequently	RB	frequently
fatal	JJ	fatal
syndromes	NNS	syndrome
.	SENT	.
T.	NP	T.
Cleavage	NP	<unknown>
of	IN	of
Ku80	NP	<unknown>
by	IN	by
caspase-2	NN	<unknown>
promotes	VVZ	promote
non-homologous	JJ	<unknown>
end	NN	end
joining-mediated	JJ	<unknown>
DNA	NN	DNA
repair	NN	repair
.	SENT	.
A.	NP	A.
Non-homologous	JJ	<unknown>
end-joining	NN	<unknown>
(	(	(
NHEJ)-mediated	JJ	<unknown>
repair	NN	repair
of	IN	of
DNA	NP	DNA
double-strand	NN	<unknown>
breaks	NNS	break
(	(	(
DSBs	NP	<unknown>
)	)	)
requires	VVZ	require
the	DT	the
formation	NN	formation
of	IN	of
a	DT	a
Ku70/Ku80/DNA-PKcs	NP	<unknown>
complex	NN	complex
at	IN	at
the	DT	the
DSB	NP	<unknown>
sites	NNS	site
.	SENT	.
A	DT	a
previous	JJ	previous
study	NN	study
has	VHZ	have
revealed	VVN	reveal
Ku80	NP	<unknown>
cleavage	NN	cleavage
by	IN	by
caspase-3	NN	<unknown>
during	IN	during
apoptosis	NN	<unknown>
.	SENT	.
However	RB	however
,	,	,
it	PP	it
remains	VVZ	remain
largely	RB	largely
unknown	JJ	unknown
whether	IN	whether
and	CC	and
how	WRB	how
Ku80	NP	<unknown>
cleavage	NN	cleavage
affects	VVZ	affect
its	PP$	its
function	NN	function
in	IN	in
mediating	VVG	mediate
NHEJ-mediated	JJ	<unknown>
DNA	NN	DNA
repair	NN	repair
.	SENT	.
Here	RB	here
we	PP	we
report	VVP	report
that	IN/that	that
Ku80	NP	<unknown>
can	MD	can
be	VB	be
cleaved	VVN	cleave
by	IN	by
caspases-2	NN	<unknown>
at	IN	at
D726	NP	<unknown>
upon	IN	upon
a	DT	a
transient	JJ	transient
etoposide	NP	etoposide
treatment	NN	treatment
.	SENT	.
Caspase-2-mediated	NP	<unknown>
Ku80	NP	<unknown>
cleavage	NN	cleavage
promotes	VVZ	promote
Ku80/DNA-PKcs	NP	<unknown>
interaction	NN	interaction
as	IN	as
the	DT	the
D726A	NP	<unknown>
mutation	NN	mutation
diminished	VVN	diminish
Ku80	NP	<unknown>
interaction	NN	interaction
with	IN	with
DNA-PKcs	NP	<unknown>
,	,	,
while	IN	while
a	DT	a
Ku80	NP	<unknown>
truncate	VV	truncate
(	(	(
Ku80	NP	<unknown>
ΔC6	NN	<unknown>
)	)	)
lacking	VVG	lack
all	PDT	all
the	DT	the
6	CD	@card@
residues	NNS	residue
following	VVG	follow
D726	NP	<unknown>
rescued	VVD	rescue
the	DT	the
weakened	JJ	weakened
Ku80/DNA-PKcs	NP	<unknown>
interaction	NN	interaction
caused	VVN	cause
by	IN	by
caspase-2	JJ	<unknown>
knockdown	NN	knockdown
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
depletion	NN	depletion
or	CC	or
inhibition	NN	inhibition
of	IN	of
caspase-2	NN	<unknown>
impairs	VVZ	impair
NHEJ-mediated	JJ	<unknown>
DNA	NN	DNA
repair	NN	repair
,	,	,
and	CC	and
such	JJ	such
impairment	NN	impairment
can	MD	can
be	VB	be
reversed	VVN	reverse
by	IN	by
Ku80	NP	<unknown>
ΔC6	NN	<unknown>
overexpression	NN	<unknown>
.	SENT	.
Taken	VVN	take
together	RB	together
,	,	,
our	PP$	our
current	JJ	current
study	NN	study
provides	VVZ	provide
a	DT	a
novel	JJ	novel
mechanism	NN	mechanism
for	IN	for
regulating	VVG	regulate
NHEJ-mediated	JJ	<unknown>
DNA	NN	DNA
repair	NN	repair
,	,	,
and	CC	and
sheds	VVZ	shed
light	NN	light
on	IN	on
the	DT	the
function	NN	function
of	IN	of
caspase-2	NN	<unknown>
in	IN	in
genomic	JJ	<unknown>
stability	NN	stability
maintenance	NN	maintenance
.	SENT	.
T.	NP	T.
The	DT	the
fecal	JJ	fecal
microbiome	NN	<unknown>
of	IN	of
ALS	JJ	<unknown>
patients	NNS	patient
.	SENT	.
A.	NP	A.
Amyotrophic	NP	<unknown>
lateral	JJ	lateral
sclerosis	NN	sclerosis
(	(	(
ALS	NN	<unknown>
)	)	)
is	VBZ	be
a	DT	a
fatal	JJ	fatal
neurodegenerative	JJ	<unknown>
motor	NN	motor
neuron	NN	neuron
disease	NN	disease
accompanied	VVN	accompany
by	IN	by
both	DT	both
systemic	JJ	systemic
and	CC	and
central	JJ	central
nervous	JJ	nervous
system-specific	NN	system-specific
inflammation	NN	inflammation
as	IN	as
well	RB	well
as	RB	as
deregulated	VVN	deregulate
energy	NN	energy
metabolism	NN	metabolism
.	SENT	.
These	DT	these
potential	JJ	potential
pathogenetic	JJ	pathogenetic
factors	NNS	factor
have	VHP	have
recently	RB	recently
been	VBN	be
found	VVN	find
to	TO	to
mutually	RB	mutually
interact	VV	interact
with	IN	with
the	DT	the
gut	NN	gut
microbiota	NN	<unknown>
,	,	,
raising	VVG	raise
the	DT	the
hypothesis	NN	hypothesis
of	IN	of
a	DT	a
link	NN	link
between	IN	between
microbiome	NN	<unknown>
alterations	NNS	alteration
and	CC	and
ALS	JJ	<unknown>
pathogenesis	NN	pathogenesis
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
our	PP$	our
study	NN	study
was	VBD	be
to	TO	to
assess	VV	assess
whether	IN	whether
ALS	NN	<unknown>
is	VBZ	be
associated	VVN	associate
with	IN	with
an	DT	an
altered	JJ	altered
composition	NN	composition
of	IN	of
the	DT	the
fecal	JJ	fecal
microbiota	NN	<unknown>
.	SENT	.
We	PP	we
compared	VVD	compare
the	DT	the
fecal	JJ	fecal
microbiota	NN	<unknown>
of	IN	of
25	CD	@card@
ALS	JJ	<unknown>
patients	NNS	patient
with	IN	with
32	CD	@card@
age-	NN	<unknown>
and	CC	and
gender-matched	JJ	<unknown>
healthy	JJ	healthy
persons	NNS	person
using	VVG	use
16S	JJ	<unknown>
rRNA	NN	<unknown>
gene	NN	gene
sequencing	VVG	sequence
analysis	NN	analysis
.	SENT	.
Confounding	VVG	confound
factors	NNS	factor
and	CC	and
secondary	JJ	secondary
disease	NN	disease
effects	NNS	effect
on	IN	on
the	DT	the
microbiome	NN	<unknown>
were	VBD	be
minimized	VVN	minimize
by	IN	by
selection	NN	selection
of	IN	of
patients	NNS	patient
without	IN	without
dysphagia	NN	dysphagia
,	,	,
gastrostomy	NN	gastrostomy
,	,	,
noninvasive	JJ	noninvasive
ventilation	NN	ventilation
,	,	,
or	CC	or
reduced	VVN	reduce
body	NN	body
mass	NN	mass
index	NN	index
.	SENT	.
Comparing	VVG	compare
the	DT	the
2	CD	@card@
carefully	RB	carefully
matched	VVN	match
groups	NNS	group
,	,	,
the	DT	the
diversity	NN	diversity
and	CC	and
the	DT	the
abundance	NN	abundance
of	IN	of
the	DT	the
bacterial	JJ	bacterial
taxa	NNS	taxon
on	IN	on
the	DT	the
different	JJ	different
taxonomic	JJ	taxonomic
levels	NNS	level
as	RB	as
well	RB	well
as	IN	as
PICRUSt-predicted	JJ	<unknown>
metagenomes	NNS	<unknown>
were	VBD	be
almost	RB	almost
indistinguishable	JJ	indistinguishable
.	SENT	.
Significant	JJ	significant
differences	NNS	difference
between	IN	between
ALS	JJ	<unknown>
patients	NNS	patient
and	CC	and
healthy	JJ	healthy
controls	NNS	control
were	VBD	be
only	RB	only
observed	VVN	observe
with	IN	with
regard	NN	regard
to	TO	to
the	DT	the
overall	JJ	overall
number	NN	number
of	IN	of
microbial	JJ	microbial
species	NNS	specie
(	(	(
operational	JJ	operational
taxonomic	JJ	taxonomic
units	NNS	unit
)	)	)
and	CC	and
in	IN	in
the	DT	the
abundance	NN	abundance
of	IN	of
uncultured	JJ	<unknown>
Ruminococcaceae	NP	<unknown>
.	SENT	.
Conclusively	RB	conclusively
,	,	,
ALS	JJ	<unknown>
patients	NNS	patient
do	VVP	do
not	RB	not
exhibit	VV	exhibit
a	DT	a
substantial	JJ	substantial
alteration	NN	alteration
of	IN	of
the	DT	the
gut	JJ	gut
microbiota	NN	<unknown>
composition	NN	composition
.	SENT	.
T.	NP	T.
Differences	NNS	difference
in	IN	in
the	DT	the
association	NN	association
of	IN	of
inflammation	NN	inflammation
and	CC	and
tryptophan	NN	tryptophan
with	IN	with
depressive	JJ	depressive
symptoms	NNS	symptom
between	IN	between
white	JJ	white
and	CC	and
non-white	JJ	non-white
chronic	JJ	chronic
dialysis	NN	dialysis
patients	NNS	patient
.	SENT	.
A.	NP	A.
Possibly	RB	possibly
,	,	,
different	JJ	different
biochemical	JJ	biochemical
parameters	NNS	parameter
are	VBP	be
involved	VVN	involve
in	IN	in
the	DT	the
development	NN	development
of	IN	of
depressive	JJ	depressive
symptoms	NNS	symptom
in	IN	in
white	JJ	white
and	CC	and
non-white	JJ	non-white
dialysis	NN	dialysis
patients	NNS	patient
.	SENT	.
We	PP	we
examined	VVD	examine
whether	IN	whether
the	DT	the
association	NN	association
between	IN	between
inflammation	NN	inflammation
and	CC	and
depressive	JJ	depressive
symptoms	NNS	symptom
and	CC	and
between	IN	between
tryptophan	NN	tryptophan
and	CC	and
depressive	JJ	depressive
symptoms	NNS	symptom
differs	VVZ	differ
between	IN	between
white	JJ	white
and	CC	and
non-white	JJ	non-white
dialysis	NN	dialysis
patients	NNS	patient
and	CC	and
whether	IN	whether
the	DT	the
association	NN	association
between	IN	between
inflammation	NN	inflammation
and	CC	and
depressive	JJ	depressive
symptoms	NNS	symptom
is	VBZ	be
mediated	VVN	mediate
by	IN	by
tryptophan	NN	tryptophan
degradation	NN	degradation
along	IN	along
the	DT	the
kynurenine	JJ	<unknown>
pathway	NN	pathway
in	IN	in
both	DT	both
groups.Depressive	JJ	<unknown>
symptoms	NNS	symptom
were	VBD	be
measured	VVN	measure
with	IN	with
the	DT	the
BDI-II	NP	<unknown>
.	SENT	.
HsCRP	NP	<unknown>
,	,	,
IL-1β	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
IL-10	NP	<unknown>
,	,	,
and	CC	and
TNFα	NP	<unknown>
and	CC	and
tryptophan	NN	tryptophan
and	CC	and
its	PP$	its
degradation	NN	degradation
products	NNS	product
kynurenine	NN	<unknown>
and	CC	and
3-hydroxykynurenine	JJ	<unknown>
were	VBD	be
measured	VVN	measure
in	IN	in
270	CD	@card@
white	NN	white
and	CC	and
220	CD	@card@
non-white	JJ	non-white
patients.The	NN	<unknown>
presence	NN	presence
of	IN	of
depressive	JJ	depressive
symptoms	NNS	symptom
was	VBD	be
significantly	RB	significantly
higher	JJR	high
in	IN	in
non-white	JJ	non-white
patients	NNS	patient
(	(	(
51	CD	@card@
%	NN	%
)	)	)
than	IN	than
in	IN	in
white	JJ	white
patients	NNS	patient
(	(	(
37	CD	@card@
%	NN	%
)	)	)
(	(	(
P&lt	NP	<unknown>
;	:	;
0.01	LS	@card@
)	)	)
.	SENT	.
Among	IN	among
white	JJ	white
patients	NNS	patient
,	,	,
HsCRP	NP	<unknown>
was	VBD	be
significantly	RB	significantly
associated	VVN	associate
with	IN	with
depressive	JJ	depressive
symptoms	NNS	symptom
(	(	(
β=0.6	NN	<unknown>
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
:	:	:
0.1-1.2	LS	@card@
)	)	)
)	)	)
.	SENT	.
Among	IN	among
non-white	JJ	non-white
patients	NNS	patient
,	,	,
significant	JJ	significant
associations	NNS	association
with	IN	with
depressive	JJ	depressive
symptoms	NNS	symptom
were	VBD	be
found	VVN	find
for	IN	for
both	DT	both
HsCRP	NP	<unknown>
(	(	(
β=1.0	NN	<unknown>
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
:	:	:
0.1-2.0	LS	@card@
)	)	)
)	)	)
and	CC	and
IL-6	NP	<unknown>
(	(	(
β=2.6	NN	<unknown>
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
:	:	:
0.8-4.4	LS	@card@
)	)	)
)	)	)
.	SENT	.
Tryptophan	NN	tryptophan
levels	NNS	level
were	VBD	be
only	RB	only
significantly	RB	significantly
associated	VVN	associate
with	IN	with
depressive	JJ	depressive
symptoms	NNS	symptom
in	IN	in
non-white	JJ	non-white
patients	NNS	patient
(	(	(
β=-0.3	NN	<unknown>
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
:	:	:
-0.4--0.1	LS	@card@
)	)	)
)	)	)
.	SENT	.
Tryptophan	NN	tryptophan
degradation	NN	degradation
along	IN	along
the	DT	the
kynurenine	NN	<unknown>
pathway	NN	pathway
did	VVD	do
not	RB	not
mediate	VV	mediate
the	DT	the
association	NN	association
between	IN	between
inflammatory	JJ	inflammatory
markers	NNS	marker
and	CC	and
depressive	JJ	depressive
symptoms	NNS	symptom
in	IN	in
either	DT	either
group.Our	NN	<unknown>
results	NNS	result
indicate	VVP	indicate
that	IN/that	that
for	IN	for
white	JJ	white
and	CC	and
non-white	JJ	non-white
dialysis	NN	dialysis
patients	NNS	patient
different	JJ	different
biochemical	JJ	biochemical
parameters	NNS	parameter
are	VBP	be
associated	VVN	associate
with	IN	with
depressive	JJ	depressive
symptoms	NNS	symptom
.	SENT	.
T.	NP	T.
Digital	NP	Digital
quantitative	JJ	quantitative
analysis	NN	analysis
of	IN	of
mast	NN	mast
cell	NN	cell
infiltration	NN	infiltration
in	IN	in
interstitial	JJ	interstitial
cystitis	NN	cystitis
.	SENT	.
A.	NP	A.
To	TO	to
evaluate	VV	evaluate
the	DT	the
significance	NN	significance
of	IN	of
mast	NN	mast
cell	NN	cell
infiltration	NN	infiltration
in	IN	in
interstitial	JJ	interstitial
cystitis	NN	cystitis
(	(	(
IC	NP	IC
)	)	)
by	IN	by
comparison	NN	comparison
with	IN	with
equally	RB	equally
inflamed	VVN	inflame
controls	NNS	control
using	VVG	use
a	DT	a
digital	JJ	digital
quantification	NN	quantification
technique.Bladder	NN	<unknown>
biopsy	NN	biopsy
specimens	NNS	specimen
from	IN	from
31	CD	@card@
patients	NNS	patient
with	IN	with
Hunner	NP	<unknown>
type	NN	type
IC	NP	IC
and	CC	and
38	CD	@card@
patients	NNS	patient
with	IN	with
non-Hunner	NP	<unknown>
type	NN	type
IC	NP	IC
were	VBD	be
analyzed	VVN	analyze
.	SENT	.
Bladder	NN	bladder
biopsy	NN	biopsy
specimens	NNS	specimen
from	IN	from
37	CD	@card@
patients	NNS	patient
without	IN	without
IC	NP	IC
,	,	,
including	VVG	include
19	CD	@card@
non-specific	JJ	<unknown>
chronic	JJ	chronic
cystitis	NN	cystitis
(	(	(
"	``	"
non-IC	JJ	<unknown>
cystitis	NN	cystitis
"	''	"
)	)	)
specimens	NNS	specimen
and	CC	and
18	CD	@card@
non-inflamed	JJ	<unknown>
bladder	NN	bladder
(	(	(
"	``	"
normal	JJ	normal
bladder	NN	bladder
"	''	"
)	)	)
specimens	NNS	specimen
,	,	,
were	VBD	be
used	VVN	use
as	IN	as
controls	NNS	control
.	SENT	.
Mast	NP	Mast
cell	NN	cell
tryptase-	NN	<unknown>
,	,	,
CD3-	NP	<unknown>
,	,	,
CD20-	NP	<unknown>
,	,	,
and	CC	and
CD138-immunoreactive	JJ	<unknown>
cells	NNS	cell
were	VBD	be
quantified	VVN	quantify
using	VVG	use
digital	JJ	digital
image	NN	image
analysis	NN	analysis
software	NN	software
to	TO	to
evaluate	VV	evaluate
both	DT	both
mast	NN	mast
cell	NN	cell
and	CC	and
lymphoplasmacytic	JJ	<unknown>
cell	NN	cell
densities	NNS	density
.	SENT	.
Mast	NN	mast
cell	NN	cell
and	CC	and
lymphoplasmacytic	JJ	<unknown>
cell	NN	cell
densities	NNS	density
were	VBD	be
counted	VVN	count
independently	RB	independently
in	IN	in
the	DT	the
entire	JJ	entire
lamina	NN	lamina
propria	NN	<unknown>
and	CC	and
detrusor	NN	<unknown>
areas	NNS	area
and	CC	and
compared	VVN	compare
among	IN	among
the	DT	the
four	CD	four
groups.In	NN	<unknown>
the	DT	the
lamina	NN	lamina
propria	NN	<unknown>
,	,	,
there	EX	there
were	VBD	be
no	DT	no
significant	JJ	significant
differences	NNS	difference
in	IN	in
mast	NN	mast
cell	NN	cell
and	CC	and
lymphoplasmacytic	JJ	<unknown>
cell	NN	cell
densities	NNS	density
between	IN	between
Hunner	NP	<unknown>
type	NN	type
IC	NP	IC
and	CC	and
non-IC	JJ	<unknown>
cystitis	NN	cystitis
or	CC	or
between	IN	between
non-Hunner	NP	<unknown>
type	NN	type
IC	NP	IC
and	CC	and
normal	JJ	normal
bladder	NN	bladder
specimens	NNS	specimen
.	SENT	.
In	IN	in
the	DT	the
detrusor	NN	<unknown>
,	,	,
the	DT	the
mast	NN	mast
cell	NN	cell
densities	NNS	density
were	VBD	be
not	RB	not
significantly	RB	significantly
different	JJ	different
among	IN	among
the	DT	the
four	CD	four
groups	NNS	group
.	SENT	.
Mast	NP	Mast
cell	NN	cell
density	NN	density
was	VBD	be
correlated	VVN	correlate
with	IN	with
lymphoplasmacytic	JJ	<unknown>
cell	NN	cell
density	NN	density
,	,	,
but	CC	but
not	RB	not
with	IN	with
clinical	JJ	clinical
parameters.Mast	NN	<unknown>
cell	NN	cell
density	NN	density
is	VBZ	be
not	RB	not
significantly	RB	significantly
different	JJ	different
between	IN	between
IC	NP	IC
specimens	NNS	specimen
and	CC	and
non-IC	JJ	<unknown>
control	NN	control
specimens	NNS	specimen
with	IN	with
a	DT	a
similar	JJ	similar
degree	NN	degree
of	IN	of
background	NN	background
inflammation	NN	inflammation
.	SENT	.
The	DT	the
intensity	NN	intensity
of	IN	of
mast	NN	mast
cell	NN	cell
infiltration	NN	infiltration
generally	RB	generally
correlated	VVN	correlate
with	IN	with
that	DT	that
of	IN	of
lymphoplasmacytic	JJ	<unknown>
cells	NNS	cell
.	SENT	.
We	PP	we
conclude	VVP	conclude
that	IN/that	that
mast	NN	mast
cell	NN	cell
count	NN	count
is	VBZ	be
of	IN	of
no	DT	no
value	NN	value
in	IN	in
the	DT	the
differential	JJ	differential
diagnosis	NN	diagnosis
between	IN	between
IC	NP	IC
and	CC	and
other	JJ	other
etiologies	NNS	etiology
.	SENT	.
T.	NP	T.
Cryopreserved	NP	<unknown>
rabbit	NN	rabbit
amniotic	JJ	amniotic
membrane	NN	membrane
alleviated	VVD	alleviate
inflammatory	JJ	inflammatory
response	NN	response
and	CC	and
fibrosis	NN	fibrosis
following	VVG	follow
experimental	JJ	experimental
strabismus	NN	strabismus
surgery	NN	surgery
in	IN	in
rabbits	NNS	rabbit
.	SENT	.
A.	NP	A.
We	PP	we
evaluate	VVP	evaluate
the	DT	the
ability	NN	ability
of	IN	of
cryopreserved	JJ	<unknown>
rabbit	NN	rabbit
amniotic	JJ	amniotic
membrane	NN	membrane
(	(	(
AM	NP	AM
)	)	)
transplantation	NN	transplantation
to	TO	to
reduce	VV	reduce
postoperative	JJ	postoperative
inflammation	NN	inflammation
and	CC	and
the	DT	the
extent	NN	extent
of	IN	of
fibrosis	NN	fibrosis
following	VVG	follow
experimental	JJ	experimental
strabismus	NN	strabismus
surgery	NN	surgery
.	SENT	.
Ten	CD	ten
white	JJ	white
rabbits	NNS	rabbit
underwent	VVD	undergo
bilateral	JJ	bilateral
superior	JJ	superior
rectus	NN	rectus
(	(	(
SR	NN	SR
)	)	)
muscle	NN	muscle
resection	NN	resection
.	SENT	.
In	IN	in
the	DT	the
left	JJ	left
eye	NN	eye
,	,	,
the	DT	the
resected	JJ	<unknown>
SR	NN	SR
muscle	NN	muscle
was	VBD	be
wrapped	VVN	wrap
with	IN	with
cryopreserved	JJ	<unknown>
rabbit	NN	rabbit
AM	NP	AM
.	SENT	.
The	DT	the
right	JJ	right
eye	NN	eye
underwent	VVD	undergo
SR	NN	SR
resection	NN	resection
only	RB	only
and	CC	and
served	VVN	serve
as	IN	as
a	DT	a
control	NN	control
.	SENT	.
The	DT	the
eyes	NNS	eye
were	VBD	be
enucleated	VVN	enucleate
4	CD	@card@
weeks	NNS	week
after	IN	after
strabismus	NN	strabismus
surgery	NN	surgery
.	SENT	.
The	DT	the
degree	NN	degree
of	IN	of
postoperative	JJ	postoperative
inflammatory	JJ	inflammatory
infiltration	NN	infiltration
,	,	,
the	DT	the
extent	NN	extent
of	IN	of
fibrosis	NN	fibrosis
,	,	,
and	CC	and
profile	NN	profile
of	IN	of
the	DT	the
relative	JJ	relative
expression	NN	expression
of	IN	of
inflammatory	JJ	inflammatory
mediators	NNS	mediator
in	IN	in
the	DT	the
SR	NN	SR
muscle	NN	muscle
were	VBD	be
evaluated	VVN	evaluate
and	CC	and
compared	VVN	compare
between	IN	between
the	DT	the
two	CD	two
groups	NNS	group
by	IN	by
histological	JJ	histological
analysis	NN	analysis
and	CC	and
real-time	JJ	real-time
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
.	SENT	.
There	EX	there
were	VBD	be
statistically	RB	statistically
meaningful	JJ	meaningful
differences	NNS	difference
in	IN	in
the	DT	the
degree	NN	degree
of	IN	of
postoperative	JJ	postoperative
inflammatory	JJ	inflammatory
infiltration	NN	infiltration
and	CC	and
extent	NN	extent
of	IN	of
fibrosis	NN	fibrosis
between	IN	between
the	DT	the
eyes	NNS	eye
treated	VVN	treat
with	IN	with
cryopreserved	JJ	<unknown>
rabbit	NNS	rabbit
AM	VBP	be
after	IN	after
SR	NN	SR
resection	NN	resection
and	CC	and
those	DT	those
underwent	VVD	undergo
SR	NN	SR
resection	NN	resection
only	RB	only
.	SENT	.
A	DT	a
significant	JJ	significant
decrease	NN	decrease
in	IN	in
the	DT	the
expression	NN	expression
of	IN	of
inflammatory	JJ	inflammatory
cytokines	NNS	<unknown>
[	SYM	[
interleukin	NN	interleukin
(	(	(
IL)-12a	NP	<unknown>
,	,	,
IL-12b	NP	<unknown>
,	,	,
IL-17f	NP	<unknown>
,	,	,
and	CC	and
tumor	NN	tumor
necrosis	NN	necrosis
factor-	NN	<unknown>
alpha	NN	alpha
(	(	(
TNF-α	NP	<unknown>
)	)	)
]	SYM	]
,	,	,
and	CC	and
a	DT	a
markedly	RB	markedly
increased	VVN	increase
expression	NN	expression
of	IN	of
anti-inflammatory	JJ	anti-inflammatory
cytokines	NNS	<unknown>
(	(	(
transforming	VVG	transform
growth	NN	growth
factor-beta-1(TGFβ-1	NN	<unknown>
)	)	)
and	CC	and
IL-10	NP	<unknown>
)	)	)
were	VBD	be
observed	VVN	observe
in	IN	in
the	DT	the
eyes	NNS	eye
treated	VVN	treat
with	IN	with
cryopreserved	JJ	<unknown>
rabbit	NN	rabbit
AM	NP	AM
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
demonstrate	VVP	demonstrate
that	IN/that	that
cryopreserved	JJ	<unknown>
rabbit	NN	rabbit
AM	NP	AM
is	VBZ	be
effective	JJ	effective
in	IN	in
reducing	VVG	reduce
postoperative	JJ	postoperative
inflammation	NN	inflammation
and	CC	and
extent	NN	extent
of	IN	of
fibrosis	NN	fibrosis
in	IN	in
a	DT	a
rabbit	NN	rabbit
model	NN	model
of	IN	of
strabismus	NN	strabismus
surgery	NN	surgery
.	SENT	.
Our	PP$	our
results	NNS	result
imply	VVP	imply
that	IN/that	that
cryopreserved	JJ	<unknown>
AM	NP	AM
allograft	NN	<unknown>
has	VHZ	have
anti-inflammatory	JJ	anti-inflammatory
and	CC	and
anti-scarring	JJ	<unknown>
properties	NNS	property
that	WDT	that
can	MD	can
prevent	VV	prevent
postoperative	JJ	postoperative
adhesions	NNS	adhesion
following	VVG	follow
strabismus	NN	strabismus
surgery	NN	surgery
.	SENT	.
T.	NP	T.
CLEC9A	NP	<unknown>
modulates	VVZ	modulate
macrophage-mediated	JJ	<unknown>
neutrophil	JJ	neutrophil
recruitment	NN	recruitment
in	IN	in
response	NN	response
to	TO	to
heat-killed	JJ	<unknown>
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
H37Ra	NP	<unknown>
.	SENT	.
A.	NP	A.
Tuberculosis	NP	<unknown>
is	VBZ	be
a	DT	a
fatal	JJ	fatal
human	JJ	human
infectious	JJ	infectious
disease	NN	disease
caused	VVN	cause
by	IN	by
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
(	(	(
M.	NP	M.
tuberculosis	NN	tuberculosis
)	)	)
that	WDT	that
is	VBZ	be
prevalent	JJ	prevalent
worldwide	RB	worldwide
.	SENT	.
Mycobacteria	NNS	mycobacterium
differ	VVP	differ
from	IN	from
other	JJ	other
bacteria	NNS	bacterium
in	IN	in
that	WDT	that
they	PP	they
have	VHP	have
a	DT	a
cell	NN	cell
wall	NN	wall
composed	VVN	compose
of	IN	of
specific	JJ	specific
surface	NN	surface
glycans	NNS	<unknown>
that	WDT	that
are	VBP	be
the	DT	the
major	JJ	major
determinant	NN	determinant
of	IN	of
these	DT	these
organisms'	NP	<unknown>
pathogenicity	NN	<unknown>
.	SENT	.
The	DT	the
interaction	NN	interaction
of	IN	of
M.	NP	M.
tuberculosis	NN	tuberculosis
with	IN	with
pattern	NN	pattern
recognition	NN	recognition
receptors	NNS	receptor
(	(	(
PRRs	NP	<unknown>
)	)	)
,	,	,
in	IN	in
particular	JJ	particular
C-type	NP	<unknown>
lectin	NN	<unknown>
receptors	NNS	receptor
(	(	(
CLRs	NP	<unknown>
)	)	)
,	,	,
on	IN	on
the	DT	the
surface	NN	surface
of	IN	of
macrophages	NNS	macrophage
plays	VVZ	play
a	DT	a
central	JJ	central
role	NN	role
in	IN	in
initiating	VVG	initiate
innate	JJ	innate
and	CC	and
adaptive	JJ	adaptive
immunity	NN	immunity
,	,	,
but	CC	but
the	DT	the
picture	NN	picture
as	IN	as
a	DT	a
whole	NN	whole
remains	VVZ	remain
a	DT	a
puzzle	NN	puzzle
.	SENT	.
Defining	VVG	define
novel	NN	novel
mechanisms	NNS	mechanism
by	IN	by
which	WDT	which
host	NN	host
receptors	NNS	receptor
interact	VVP	interact
with	IN	with
pathogens	NNS	pathogen
in	IN	in
order	NN	order
to	TO	to
modulate	VV	modulate
a	DT	a
specific	JJ	specific
immune	JJ	immune
response	NN	response
is	VBZ	be
an	DT	an
area	NN	area
of	IN	of
intense	JJ	intense
research	NN	research
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
based	VVN	base
on	IN	on
an	DT	an
in	IN	in
vitro	NP	Vitro
lectin	NP	<unknown>
binding	JJ	binding
assay	NN	assay
,	,	,
CLEC9A	NP	<unknown>
(	(	(
DNGR-1	NP	<unknown>
)	)	)
is	VBZ	be
identified	VVN	identify
as	IN	as
a	DT	a
novel	JJ	novel
CLR	NP	<unknown>
that	IN/that	that
binds	NNS	bind
with	IN	with
mycobacteria	NNS	mycobacterium
.	SENT	.
Our	PP$	our
results	NNS	result
with	IN	with
CLEC9A-knocked	JJ	<unknown>
down	JJ	down
cells	NNS	cell
and	CC	and
a	DT	a
CLEC9A-Fc	NP	<unknown>
fusion	NN	fusion
protein	NN	protein
as	IN	as
blocking	VVG	block
agents	NNS	agent
show	VVP	show
that	IN/that	that
CLEC9A	NP	<unknown>
is	VBZ	be
involved	VVN	involve
in	IN	in
the	DT	the
activation	NN	activation
of	IN	of
SYK	NP	<unknown>
and	CC	and
MAPK	NP	<unknown>
signaling	VVG	signal
in	IN	in
response	NN	response
to	TO	to
heat-killed	JJ	<unknown>
M.	NP	M.
tuberculosis	NN	tuberculosis
H37Ra	NP	<unknown>
treatment	NN	treatment
,	,	,
and	CC	and
it	PP	it
then	RB	then
promotes	VVZ	promote
the	DT	the
production	NN	production
of	IN	of
CXCL8	NP	<unknown>
and	CC	and
IL-1β	NP	<unknown>
in	IN	in
macrophages	NNS	macrophage
.	SENT	.
The	DT	the
CXCL8	NP	<unknown>
and	CC	and
IL-1β	NP	<unknown>
secreted	VVD	secrete
by	IN	by
the	DT	the
activated	VVN	activate
macrophages	NNS	macrophage
are	VBP	be
critical	JJ	critical
to	TO	to
neutrophil	JJ	neutrophil
recruitment	NN	recruitment
and	CC	and
activation	NN	activation
.	SENT	.
In	IN	in
a	DT	a
in	IN	in
vivo	JJ	vivo
mouse	NN	mouse
model	NN	model
,	,	,
when	WRB	when
the	DT	the
interaction	NN	interaction
between	IN	between
CLEC9A	NP	<unknown>
and	CC	and
H37Ra	NP	<unknown>
is	VBZ	be
interfered	VVN	interfere
with	IN	with
by	IN	by
treatment	NN	treatment
with	IN	with
CLEC9A-Fc	NP	<unknown>
fusion	NN	fusion
protein	NN	protein
,	,	,
this	DT	this
reduces	VVZ	reduce
lung	NN	lung
inflammation	NN	inflammation
and	CC	and
cell	NN	cell
infiltration	NN	infiltration
.	SENT	.
These	DT	these
findings	NNS	finding
demonstrate	VVP	demonstrate
that	IN/that	that
CLEC9A	NP	<unknown>
is	VBZ	be
a	DT	a
specialized	JJ	specialized
receptor	NN	receptor
that	WDT	that
modulates	VVZ	modulate
the	DT	the
innate	JJ	innate
immune	JJ	immune
response	NN	response
when	WRB	when
there	EX	there
is	VBZ	be
a	DT	a
mycobacterial	JJ	<unknown>
infection	NN	infection
.	SENT	.
T.	NP	T.
Severe	NP	Severe
Burn-Induced	NP	<unknown>
Inflammation	NP	<unknown>
and	CC	and
Remodeling	NP	<unknown>
of	IN	of
Achilles	NP	Achilles
Tendon	NP	<unknown>
in	IN	in
a	DT	a
Rat	NP	<unknown>
Model	NP	Model
.	SENT	.
A.	NP	A.
Severe	NP	Severe
burn	NN	burn
causes	VVZ	cause
systemic	JJ	systemic
inflammation	NN	inflammation
and	CC	and
hypercatabolism	NN	<unknown>
,	,	,
resulting	VVG	result
in	IN	in
damage	NN	damage
to	TO	to
multiple	JJ	multiple
organs	NNS	organ
distant	JJ	distant
to	TO	to
the	DT	the
burn	NN	burn
site	NN	site
,	,	,
including	VVG	include
the	DT	the
musculoskeletal	JJ	musculoskeletal
system	NN	system
.	SENT	.
Bone	NN	bone
mass	NN	mass
and	CC	and
muscle	NN	muscle
loss	NN	loss
have	VHP	have
been	VBN	be
reported	VVN	report
.	SENT	.
However	RB	however
,	,	,
tendon	NN	tendon
that	WDT	that
connects	VVZ	connect
bone	NN	bone
and	CC	and
muscle	NN	muscle
has	VHZ	have
not	RB	not
been	VBN	be
studied	VVN	study
in	IN	in
comparable	JJ	comparable
detail	NN	detail
.	SENT	.
Here	RB	here
we	PP	we
aimed	VVD	aim
to	TO	to
characterize	VV	characterize
the	DT	the
molecular	JJ	molecular
and	CC	and
functional	JJ	functional
changes	NNS	change
in	IN	in
Achilles	NP	Achilles
tendon	NN	tendon
triggered	VVN	trigger
by	IN	by
severe	JJ	severe
burn	NN	burn
.	SENT	.
Forty	NN	forty
male	JJ	male
Sprague-Dawley	NP	<unknown>
rats	NNS	rat
received	VVD	receive
40	CD	@card@
%	NN	%
total	JJ	total
body	NN	body
surface	NN	surface
area	NN	area
scald	NN	scald
burn	NN	burn
.	SENT	.
Achilles	NP	Achilles
tendons	NNS	tendon
were	VBD	be
collected	VVN	collect
up	RP	up
to	TO	to
14	CD	@card@
days	NNS	day
post	IN	post
burn	NN	burn
.	SENT	.
Sham-treated	JJ	<unknown>
animals	NNS	animal
served	VVN	serve
as	IN	as
a	DT	a
control	NN	control
group	NN	group
.	SENT	.
We	PP	we
analyzed	VVD	analyze
tendons	NNS	tendon
for	IN	for
changes	NNS	change
in	IN	in
expression	NN	expression
of	IN	of
IL-6	NP	<unknown>
,	,	,
IL-1β	NP	<unknown>
,	,	,
TNF	NP	TNF
,	,	,
MMP9	NP	<unknown>
,	,	,
MMP13	NP	<unknown>
,	,	,
TGFβ1	NP	<unknown>
,	,	,
Collagens	NP	<unknown>
I	NP	I
and	CC	and
III	NP	III
,	,	,
and	CC	and
for	IN	for
morphological	JJ	morphological
and	CC	and
biomechanical	JJ	biomechanical
changes	NNS	change
.	SENT	.
Gene	NN	gene
expression	NN	expression
of	IN	of
IL-6	NP	<unknown>
and	CC	and
IL-1β	NP	<unknown>
as	RB	as
well	RB	well
as	IN	as
MMP9	NP	<unknown>
and	CC	and
MMP13	NP	<unknown>
increased	VVD	increase
in	IN	in
rat	NN	rat
tendon	NN	tendon
3	CD	@card@
days	NNS	day
after	IN	after
burn	NN	burn
.	SENT	.
Col3a1	NP	<unknown>
increased	VVD	increase
at	IN	at
day	NN	day
3	CD	@card@
and	CC	and
col1a1	JJ	<unknown>
at	IN	at
day	NN	day
7.	CD	@ord@
At	IN	at
day	NN	day
14	CD	@card@
,	,	,
TGFβ1	NP	<unknown>
increased	VVD	increase
while	IN	while
the	DT	the
protein	NN	protein
ratio	NN	ratio
for	IN	for
collagens	NNS	collagen
I/III	NP	<unknown>
decreased	VVD	decrease
,	,	,
indicating	VVG	indicate
tendon	NN	tendon
remodeling	NN	remodeling
.	SENT	.
Histological	JJ	histological
analysis	NN	analysis
with	IN	with
H&amp	NP	<unknown>
;	:	;
E	NP	E
and	CC	and
Picrosirius	NP	<unknown>
red	NN	red
staining	VVG	stain
further	JJR	further
revealed	VVD	reveal
a	DT	a
decrease	NN	decrease
in	IN	in
organized	JJ	organized
collagen	NN	collagen
fibers	NNS	fiber
14	CD	@card@
days	NNS	day
after	IN	after
burn	NN	burn
.	SENT	.
Biomechanical	JJ	biomechanical
analysis	NN	analysis
showed	VVD	show
a	DT	a
decrease	NN	decrease
in	IN	in
stiffness	NN	stiffness
and	CC	and
ultimate	JJ	ultimate
force	NN	force
of	IN	of
tendons	NNS	tendon
in	IN	in
burn	NN	burn
rats.We	NNS	<unknown>
conclude	VVP	conclude
that	IN/that	that
tendinopathy	NN	<unknown>
was	VBD	be
observed	VVN	observe
in	IN	in
Achilles	NP	Achilles
tendon	NN	tendon
14	CD	@card@
days	NNS	day
after	IN	after
severe	JJ	severe
burn	NN	burn
,	,	,
via	IN	via
the	DT	the
induction	NN	induction
of	IN	of
inflammation	NN	inflammation
and	CC	and
remodeling	NN	remodeling
.	SENT	.
The	DT	the
current	JJ	current
study	NN	study
provides	VVZ	provide
a	DT	a
model	NN	model
of	IN	of
tendinopathy	NN	<unknown>
that	WDT	that
may	MD	may
be	VB	be
used	VVN	use
for	IN	for
the	DT	the
development	NN	development
of	IN	of
therapeutic	JJ	therapeutic
approaches	NNS	approach
following	VVG	follow
burn.This	NNS	<unknown>
is	VBZ	be
an	DT	an
open-access	NN	open-access
article	NN	article
distributed	VVN	distribute
under	IN	under
the	DT	the
terms	NNS	term
of	IN	of
the	DT	the
Creative	NP	Creative
Commons	NP	Commons
Attribution-Non	NP	<unknown>
Commercial-No	NP	<unknown>
Derivatives	NP	<unknown>
License	NP	License
4.0	NP	@card@
(	(	(
CCBY-NC-ND	NP	<unknown>
)	)	)
,	,	,
where	WRB	where
it	PP	it
is	VBZ	be
permissible	JJ	permissible
to	TO	to
download	VV	<unknown>
and	CC	and
share	VV	share
the	DT	the
work	NN	work
provided	VVD	provide
it	PP	it
is	VBZ	be
properly	RB	properly
cited	VVN	cite
.	SENT	.
The	DT	the
work	NN	work
cannot	MD	can
be	VB	be
changed	VVN	change
in	IN	in
any	DT	any
way	NN	way
or	CC	or
used	VVN	use
commercially	RB	commercially
without	IN	without
permission	NN	permission
from	IN	from
the	DT	the
journal	NN	journal
.	SENT	.
http://creativecommons.org/licenses/by-nc-nd/4.0	NN	<unknown>
.	SENT	.
T.	NP	T.
CLINICAL	NP	<unknown>
COURSE	NP	Course
OF	IN	of
INFLAMMATORY	NP	<unknown>
CHOROIDAL	NP	<unknown>
NEOVASCULARIZATION	NP	<unknown>
ASSOCIATED	NP	Associated
WITH	NP	<unknown>
FOCAL	NP	<unknown>
CHOROIDAL	NP	<unknown>
EXCAVATION	NP	<unknown>
.	SENT	.
A.	NP	A.
To	TO	to
report	VV	report
the	DT	the
clinical	JJ	clinical
course	NN	course
of	IN	of
focal	JJ	focal
choroidal	JJ	<unknown>
excavation	NN	excavation
associated	VVN	associate
with	IN	with
choroidal	JJ	<unknown>
neovascularization	NN	<unknown>
in	IN	in
a	DT	a
case	NN	case
of	IN	of
choroidal	JJ	<unknown>
inflammation.Case	NN	<unknown>
report.A	NN	<unknown>
41-year-old	JJ	41-year-old
man	NN	man
presented	VVN	present
with	IN	with
blurred	VVN	blur
vision	NN	vision
and	CC	and
metamorphopsia	NN	<unknown>
in	IN	in
his	PP$	his
left	JJ	left
eye	NN	eye
.	SENT	.
Multimodal	JJ	multimodal
imaging	NN	imaging
including	VVG	include
optical	JJ	optical
coherence	NN	coherence
tomography	NN	tomography
angiography	NN	angiography
showed	VVD	show
nonconforming	JJ	<unknown>
focal	JJ	focal
choroidal	JJ	<unknown>
excavation	NN	excavation
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
choroidal	JJ	<unknown>
inflammation	NN	inflammation
and	CC	and
the	DT	the
presence	NN	presence
of	IN	of
choroidal	JJ	<unknown>
neovascularization	NN	<unknown>
at	IN	at
the	DT	the
border	NN	border
of	IN	of
the	DT	the
excavation	NN	excavation
,	,	,
nicely	RB	nicely
visualized	VVN	visualize
by	IN	by
optical	JJ	optical
coherence	NN	coherence
tomography	NN	tomography
angiography	NN	angiography
.	SENT	.
Pattern	NN	pattern
alteration	NN	alteration
from	IN	from
nonconforming	NN	<unknown>
to	TO	to
conforming	VVG	conform
focal	JJ	focal
choroidal	JJ	<unknown>
excavation	NN	excavation
and	CC	and
choroidal	JJ	<unknown>
neovascularization	NN	<unknown>
involution	NN	involution
were	VBD	be
observed	VVN	observe
after	IN	after
treatment	NN	treatment
with	IN	with
oral	JJ	oral
steroids.Multimodal	JJ	<unknown>
imaging	NN	imaging
,	,	,
including	VVG	include
optical	JJ	optical
coherence	NN	coherence
tomography	NN	tomography
angiography	NN	angiography
,	,	,
allowed	VVN	allow
to	TO	to
detect	VV	detect
and	CC	and
monitor	VV	monitor
pattern	NN	pattern
focal	JJ	focal
choroidal	JJ	<unknown>
excavation	NN	excavation
transformation	NN	transformation
and	CC	and
choroidal	JJ	<unknown>
neovascularization	NN	<unknown>
reduction	NN	reduction
after	IN	after
treatment	NN	treatment
with	IN	with
oral	JJ	oral
steroids	NNS	steroid
.	SENT	.
T.	NP	T.
Age-related	JJ	age-related
decline	NN	decline
of	IN	of
the	DT	the
acute	JJ	acute
local	JJ	local
inflammation	NN	inflammation
response	NN	response
:	:	:
a	DT	a
mitigating	JJ	mitigating
role	NN	role
for	IN	for
the	DT	the
adenosine	NN	adenosine
A2A	NP	<unknown>
receptor	NN	receptor
.	SENT	.
A.	NP	A.
Aging	NP	<unknown>
is	VBZ	be
accompanied	VVN	accompany
by	IN	by
an	DT	an
increase	NN	increase
in	IN	in
markers	NNS	marker
of	IN	of
innate	JJ	innate
immunity	NN	immunity
.	SENT	.
How	WRB	how
aging	NN	aging
affects	VVZ	affect
neutrophil	JJ	neutrophil
functions	NNS	function
remains	VVZ	remain
of	IN	of
debate.The	NN	<unknown>
adenosine	NN	adenosine
A2A	NP	<unknown>
receptor	NN	receptor
(	(	(
A2AR	NP	<unknown>
)	)	)
,	,	,
essential	JJ	essential
to	TO	to
the	DT	the
resolution	NN	resolution
of	IN	of
inflammation	NN	inflammation
,	,	,
modulates	VVZ	modulate
neutrophil	JJ	neutrophil
functions	NNS	function
.	SENT	.
We	PP	we
sought	VVD	seek
to	TO	to
determine	VV	determine
whether	IN	whether
or	CC	or
not	RB	not
A2AR	NP	<unknown>
protects	VVZ	protect
against	IN	against
the	DT	the
effects	NNS	effect
of	IN	of
aging	VVG	age
.	SENT	.
We	PP	we
monitored	VVD	monitor
neutrophil	JJ	neutrophil
influx	NN	influx
,	,	,
viability	NN	viability
,	,	,
and	CC	and
activation	NN	activation
as	RB	as
well	RB	well
as	IN	as
cytokine	NN	<unknown>
accumulation	NN	accumulation
in	IN	in
wild-type	NN	<unknown>
(	(	(
WT	NP	<unknown>
)	)	)
and	CC	and
A2AR-knockout	NP	<unknown>
mice	NNS	mouse
(	(	(
KO	NP	KO
)	)	)
at	IN	at
three	CD	three
different	JJ	different
ages.Several	JJ	<unknown>
readouts	NNS	readout
decreased	VVN	decrease
with	IN	with
aging	VVG	age
:	:	:
neutrophil	JJ	neutrophil
counts	NNS	count
in	IN	in
dorsal	JJ	dorsal
air	NN	air
pouches	NNS	pouch
(	(	(
by	IN	by
up	IN	up
to	TO	to
55	CD	@card@
%	NN	%
)	)	)
,	,	,
neutrophil	JJ	neutrophil
viability	NN	viability
(	(	(
by	IN	by
up	IN	up
to	TO	to
56	CD	@card@
%	NN	%
)	)	)
,	,	,
elastase	NN	<unknown>
and	CC	and
total	JJ	total
protein	NN	protein
in	IN	in
exudates	NNS	<unknown>
(	(	(
by	IN	by
up	IN	up
to	TO	to
80	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
local	JJ	local
levels	NNS	level
of	IN	of
cytokines	NNS	<unknown>
(	(	(
by	IN	by
up	IN	up
to	TO	to
90	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Each	DT	each
of	IN	of
these	DT	these
parameters	NNS	parameter
was	VBD	be
significantly	RB	significantly
more	RBR	more
affected	VVN	affect
in	IN	in
A2AR-KO	NP	<unknown>
mice	NNS	mouse
.	SENT	.
CXCL1-3	NP	<unknown>
levels	NNS	level
were	VBD	be
largely	RB	largely
unaffected	JJ	unaffected
.	SENT	.
The	DT	the
effects	NNS	effect
of	IN	of
aging	NN	aging
were	VBD	be
not	RB	not
observed	VVN	observe
systemically	RB	systemically
.	SENT	.
Preventing	VVG	prevent
neutrophil	JJ	neutrophil
influx	NN	influx
into	IN	into
the	DT	the
air	NN	air
pouch	NN	pouch
caused	VVD	cause
a	DT	a
comparable	JJ	comparable
cytokine	NN	<unknown>
pattern	NN	pattern
in	IN	in
young	JJ	young
WT	NP	<unknown>
mice	NNS	mouse
.	SENT	.
Gene	NN	gene
expression	NN	expression
(	(	(
mRNA	NN	<unknown>
)	)	)
in	IN	in
leukocytes	NNS	<unknown>
was	VBD	be
affected	VVN	affect
,	,	,
with	IN	with
CXCL1	NP	<unknown>
and	CC	and
CCL4	NP	<unknown>
increasing	VVG	increase
and	CC	and
with	IN	with
TNF	NP	TNF
and	CC	and
IL-1α	NP	<unknown>
decreasing.ConclusionAging	NN	<unknown>
has	VHZ	have
deleterious	JJ	deleterious
effects	NNS	effect
on	IN	on
the	DT	the
acute	JJ	acute
inflammatory	JJ	inflammatory
response	NN	response
and	CC	and
neutrophil-related	JJ	<unknown>
activities	NNS	activity
,	,	,
and	CC	and
defective	JJ	defective
migration	NN	migration
appears	VVZ	appear
as	IN	as
an	DT	an
important	JJ	important
factor	NN	factor
.	SENT	.
A	DT	a
functional	JJ	functional
A2AR	NP	<unknown>
signaling	VVG	signal
pathway	NN	pathway
delays	NNS	delay
some	RB	some
of	IN	of
these	DT	these
.	SENT	.
T.	NP	T.
[	SYM	[
Dental	JJ	dental
perspective	NN	perspective
on	IN	on
Crohn	NP	<unknown>
's	POS	's
disease	NN	disease
:	:	:
literature	NN	literature
review	NN	review
]	SYM	]
.	SENT	.
A.	NP	A.
Crohn	NP	<unknown>
's	POS	's
disease	NN	disease
(	(	(
CD	NN	CD
)	)	)
is	VBZ	be
a	DT	a
chronic	JJ	chronic
,	,	,
idiophatic	JJ	<unknown>
inflammatory	JJ	inflammatory
process	NN	process
of	IN	of
the	DT	the
gastrointestinal	JJ	gastrointestinal
tract	NN	tract
and	CC	and
its	PP$	its
cause	NN	cause
remains	VVZ	remain
unknown	JJ	unknown
.	SENT	.
It	PP	it
can	MD	can
affect	VV	affect
any	DT	any
part	NN	part
of	IN	of
the	DT	the
digestive	JJ	digestive
system	NN	system
,	,	,
but	CC	but
preferentially	RB	preferentially
involves	VVZ	involve
the	DT	the
terminal	JJ	terminal
part	NN	part
of	IN	of
the	DT	the
small	JJ	small
intestine	NN	intestine
and	CC	and
the	DT	the
beginning	NN	beginning
of	IN	of
the	DT	the
large	JJ	large
intestine	NN	intestine
.	SENT	.
The	DT	the
disease	NN	disease
course	NN	course
is	VBZ	be
usually	RB	usually
long-term	JJ	long-term
with	IN	with
episodes	NNS	episode
of	IN	of
remission	NN	remission
and	CC	and
relapses	NNS	relapse
.	SENT	.
The	DT	the
clinical	JJ	clinical
presentation	NN	presentation
of	IN	of
the	DT	the
disease	NN	disease
varies	VVZ	vary
and	CC	and
depends	VVZ	depend
on	IN	on
the	DT	the
site	NN	site
of	IN	of
inflammation	NN	inflammation
.	SENT	.
Oral	JJ	oral
lesions	NNS	lesion
can	MD	can
occur	VV	occur
in	IN	in
80	CD	@card@
%	NN	%
of	IN	of
pediatric	JJ	pediatric
and	CC	and
90	CD	@card@
%	NN	%
of	IN	of
adult	JJ	adult
patients	NNS	patient
with	IN	with
CD	NN	CD
.	SENT	.
The	DT	the
most	RBS	most
frequent	JJ	frequent
are	VBP	be
swelling	VVG	swell
of	IN	of
the	DT	the
oral	JJ	oral
mucosa	NN	mucosa
with	IN	with
surface	NN	surface
cobblestoning	NN	<unknown>
,	,	,
ulcerations	NNS	ulceration
,	,	,
candidiasis	NN	<unknown>
,	,	,
angular	JJ	angular
cheilitis	NN	<unknown>
.	SENT	.
The	DT	the
difficulty	NN	difficulty
in	IN	in
diagnosis	NN	diagnosis
,	,	,
resulting	VVG	result
from	IN	from
the	DT	the
non-specific	JJ	<unknown>
clinical	JJ	clinical
manifestation	NN	manifestation
,	,	,
hamper	VV	hamper
proper	JJ	proper
diagnosis	NN	diagnosis
and	CC	and
delay	VV	delay
the	DT	the
start	NN	start
of	IN	of
treatment	NN	treatment
.	SENT	.
This	DT	this
paper	NN	paper
presents	VVZ	present
etiology	NN	etiology
,	,	,
epidemiology	NN	epidemiology
,	,	,
clinical	JJ	clinical
features	NNS	feature
and	CC	and
basic	JJ	basic
therapeutic	JJ	therapeutic
capabilities	NNS	capability
for	IN	for
CD	NN	CD
in	IN	in
the	DT	the
light	NN	light
of	IN	of
the	DT	the
literature	NN	literature
.	SENT	.
Oral	JJ	oral
manifestation	NN	manifestation
of	IN	of
this	DT	this
disease	NN	disease
was	VBD	be
particularly	RB	particularly
emphasized	VVN	emphasize
.	SENT	.
T.	NP	T.
[	SYM	[
Modern	NP	Modern
perspective	NN	perspective
on	IN	on
the	DT	the
development	NN	development
conditions	NNS	condition
and	CC	and
diagnosis	NN	diagnosis
of	IN	of
systemic	JJ	systemic
sclerosis	NN	sclerosis
]	SYM	]
.	SENT	.
A.	NP	A.
Systemic	NP	<unknown>
sclerosis	NN	sclerosis
(	(	(
SSc	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
multisystem	NN	<unknown>
disorder	NN	disorder
of	IN	of
the	DT	the
connective	JJ	connective
tissue	NN	tissue
characterized	VVN	characterize
by	IN	by
a	DT	a
great	JJ	great
deal	NN	deal
of	IN	of
heterogeneity	NN	heterogeneity
.	SENT	.
This	DT	this
variability	NN	variability
is	VBZ	be
a	DT	a
result	NN	result
of	IN	of
a	DT	a
combination	NN	combination
of	IN	of
vascular	JJ	vascular
damage	NN	damage
inflammation	NN	inflammation
and	CC	and
fibrosis	NN	fibrosis
leading	VVG	lead
to	TO	to
internal	JJ	internal
organ	NN	organ
complications	NNS	complication
.	SENT	.
The	DT	the
pathogenesis	NN	pathogenesis
of	IN	of
disorder	NN	disorder
is	VBZ	be
still	RB	still
unknown	JJ	unknown
.	SENT	.
A	DT	a
large	JJ	large
part	NN	part
is	VBZ	be
given	VVN	give
to	TO	to
genetic	JJ	genetic
,	,	,
epigenetic	JJ	epigenetic
and	CC	and
environmental	JJ	environmental
factors	NNS	factor
.	SENT	.
There	EX	there
is	VBZ	be
ongoing	JJ	ongoing
research	NN	research
into	IN	into
the	DT	the
new	JJ	new
cells	NNS	cell
and	CC	and
mediators	NNS	mediator
involved	VVN	involve
in	IN	in
the	DT	the
complicated	JJ	complicated
development	NN	development
of	IN	of
disease	NN	disease
.	SENT	.
The	DT	the
overlap	VVP	overlap
of	IN	of
vascular	JJ	vascular
,	,	,
autoimmune/	JJ	<unknown>
inflammatory	JJ	inflammatory
alternations	NNS	alternation
and	CC	and
fibrosis	NN	fibrosis
causes	VVZ	cause
the	DT	the
multidirectional	JJ	multidirectional
and	CC	and
unpredictable	JJ	unpredictable
course	NN	course
of	IN	of
disease	NN	disease
.	SENT	.
Vascular	JJ	vascular
complications	NNS	complication
may	MD	may
dominate	VV	dominate
in	IN	in
one	CD	one
group	NN	group
,	,	,
whereas	IN	whereas
fibrosis	NN	fibrosis
in	IN	in
others	NNS	other
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
the	DT	the
disorder	NN	disorder
is	VBZ	be
characterized	VVN	characterize
by	IN	by
individual	JJ	individual
variability	NN	variability
;	:	;
therefore	RB	therefore
although	IN	although
certain	JJ	certain
prognostic	JJ	prognostic
markers	NNS	marker
do	VVP	do
exist	VV	exist
,	,	,
the	DT	the
course	NN	course
of	IN	of
disorder	NN	disorder
in	IN	in
largely	RB	largely
unpredictable	JJ	unpredictable
.	SENT	.
This	DT	this
complexity	NN	complexity
of	IN	of
SSc	NP	<unknown>
,	,	,
makes	VVZ	make
it	PP	it
difficult	JJ	difficult
in	IN	in
terms	NNS	term
of	IN	of
diagnosis	NN	diagnosis
and	CC	and
activity	NN	activity
assessment	NN	assessment
,	,	,
especially	RB	especially
in	IN	in
early	JJ	early
stages	NNS	stage
.	SENT	.
Over	IN	over
a	DT	a
number	NN	number
of	IN	of
years	NNS	year
,	,	,
further	JJR	further
classification	NN	classification
criteria	NNS	criterion
,	,	,
which	WDT	which
were	VBD	be
more	RBR	more
sensitive	JJ	sensitive
and	CC	and
more	RBR	more
specific	JJ	specific
,	,	,
were	VBD	be
developed	VVN	develop
.	SENT	.
The	DT	the
2013	CD	@card@
European	NP	European
League	NP	League
Against	IN	against
Rheumatism/American	NP	<unknown>
College	NP	College
of	IN	of
Rheumatology	NP	<unknown>
-	:	-
EULAR/ACR	NP	<unknown>
classification	NN	classification
criteria	NNS	criterion
for	IN	for
SSc	NP	<unknown>
,	,	,
were	VBD	be
revised	VVN	revise
to	TO	to
include	VV	include
diagnosis	NN	diagnosis
in	IN	in
early	JJ	early
stages	NNS	stage
and	CC	and
particularly	RB	particularly
in	IN	in
limited	JJ	limited
SSc	NP	<unknown>
.	SENT	.
Unfortunately	RB	unfortunately
,	,	,
there	EX	there
still	RB	still
exist	VV	exist
certain	JJ	certain
groups	NNS	group
of	IN	of
population	NN	population
which	WDT	which
do	VVP	do
not	RB	not
fulfil	VV	fulfil
these	DT	these
criteria	NNS	criterion
but	CC	but
develop	VV	develop
the	DT	the
disorder	NN	disorder
;	:	;
therefore	RB	therefore
,	,	,
the	DT	the
search	NN	search
for	IN	for
new	JJ	new
diagnostic	JJ	diagnostic
methods	NNS	method
which	WDT	which
could	MD	could
elevate	VV	elevate
SSc	NP	<unknown>
diagnosis	NN	diagnosis
continues	VVZ	continue
.	SENT	.
T.	NP	T.
[	SYM	[
Parathormone	NN	<unknown>
and	CC	and
vitamin	NN	vitamin
d	NN	d
in	IN	in
heart	NN	heart
failure	NN	failure
-	:	-
theoretical	JJ	theoretical
influence	NN	influence
on	IN	on
disease	NN	disease
development	NN	development
and	CC	and
potential	JJ	potential
therapy	NN	therapy
targets	NNS	target
]	SYM	]
.	SENT	.
A.	NP	A.
Vitamin	NP	<unknown>
D	NP	D
and	CC	and
parathormone	NP	<unknown>
(	(	(
PTH	NP	<unknown>
)	)	)
are	VBP	be
hormones	NNS	hormone
regulating	VVG	regulate
calcium	NN	calcium
and	CC	and
phosphorus	NN	phosphorus
homeostasis	NN	homeostasis
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
the	DT	the
article	NN	article
is	VBZ	be
to	TO	to
summarize	VV	summarize
the	DT	the
current	JJ	current
knowledge	NN	knowledge
in	IN	in
the	DT	the
field	NN	field
and	CC	and
to	TO	to
assess	VV	assess
its	PP$	its
impact	NN	impact
on	IN	on
heart	NN	heart
failure	NN	failure
(	(	(
HF	NP	HF
)	)	)
pathogenesis	NN	pathogenesis
.	SENT	.
PTH	NP	<unknown>
serum	NN	serum
concentration	NN	concentration
being	VBG	be
frequently	RB	frequently
elevated	VVN	elevate
in	IN	in
patients	NNS	patient
with	IN	with
HF	NP	HF
has	VHZ	have
negative	JJ	negative
impact	NN	impact
on	IN	on
circulatory	JJ	circulatory
system	NN	system
stimulating	VVG	stimulate
myocardial	JJ	myocardial
fibrosis	NN	fibrosis
,	,	,
wall	NN	wall
thickening	NN	thickening
and	CC	and
reninangiotensin-aldosterone	NN	<unknown>
system	NN	system
(	(	(
RAAS	NP	<unknown>
)	)	)
activity	NN	activity
.	SENT	.
PTH	NP	<unknown>
reacts	VVZ	react
with	IN	with
smooth	JJ	smooth
muscle	NN	muscle
cells	NNS	cell
receptors	NNS	receptor
mediating	VVG	mediate
adrenergic	JJ	adrenergic
and	CC	and
chronotropic	JJ	<unknown>
activation	NN	activation
resulting	VVG	result
in	IN	in
increased	VVN	increase
oxidative	JJ	oxidative
stress	NN	stress
,	,	,
endothelial	JJ	endothelial
dysfunction	NN	dysfunction
,	,	,
intracellular	JJ	intracellular
calcium	NN	calcium
overload	NN	overload
and	CC	and
has	VHZ	have
negative	JJ	negative
influence	NN	influence
on	IN	on
prognosis	NN	prognosis
in	IN	in
chronic	JJ	chronic
HF	NP	HF
patients	NNS	patient
.	SENT	.
Vitamin	NN	vitamin
D	NP	D
,	,	,
which	WDT	which
deficiency	NN	deficiency
is	VBZ	be
common	JJ	common
in	IN	in
developed	JJ	developed
countries	NNS	country
,	,	,
has	VHZ	have
widely	RB	widely
distributed	VVN	distribute
receptors	NNS	receptor
including	VVG	include
myocardium	NN	myocardium
,	,	,
endothelium	NN	endothelium
and	CC	and
smooth	JJ	smooth
muscle	NN	muscle
cells	NNS	cell
.	SENT	.
Being	VBG	be
an	DT	an
antiproliferative	JJ	<unknown>
agent	NN	agent
vitamin	NN	vitamin
D	NP	D
modulates	VVZ	modulate
RAAS	NP	<unknown>
,	,	,
regulates	VVZ	regulate
natriuretic	NN	<unknown>
peptides	NNS	peptide
and	CC	and
myosine	NN	<unknown>
expression	NN	expression
,	,	,
suppresses	VVZ	suppress
inflammatory	JJ	inflammatory
cytokines	NNS	<unknown>
activity	NN	activity
,	,	,
has	VHZ	have
antiarrhytmic	JJ	<unknown>
properties	NNS	property
and	CC	and
increases	VVZ	increase
myocardial	JJ	myocardial
contractility	NN	contractility
.	SENT	.
It	PP	it
decreases	VVZ	decrease
arterial	JJ	arterial
pressure	NN	pressure
,	,	,
inhibits	VVZ	inhibit
atherosclerosis	NN	atherosclerosis
progression	NN	progression
and	CC	and
plays	VVZ	play
a	DT	a
protective	JJ	protective
role	NN	role
against	IN	against
inflammation	NN	inflammation
including	VVG	include
viral	JJ	viral
infections	NNS	infection
of	IN	of
cardiotropic	JJ	<unknown>
potential	NN	potential
.	SENT	.
Optimal	JJ	optimal
vitamin	NN	vitamin
D	NP	D
serum	NN	serum
concentration	NN	concentration
has	VHZ	have
potential	JJ	potential
protective	JJ	protective
impact	NN	impact
on	IN	on
cardiovascular	JJ	cardiovascular
system	NN	system
.	SENT	.
T.	NP	T.
Anti-inflammatory	NN	<unknown>
and	CC	and
endothelium	NN	endothelium
protective	JJ	protective
effect	NN	effect
of	IN	of
long-term	JJ	long-term
pioglitazone	NN	<unknown>
intake	NN	intake
in	IN	in
patients	NNS	patient
suffering	VVG	suffer
from	IN	from
bronchial	JJ	bronchial
asthma	NN	asthma
concurrent	NN	concurrent
with	IN	with
ischemic	JJ	ischemic
heart	NN	heart
disease	NN	disease
.	SENT	.
A.	NP	A.
Treatment	NP	Treatment
of	IN	of
co-morbidities	NNS	<unknown>
,	,	,
including	VVG	include
bronchial	JJ	bronchial
asthma	NN	asthma
(	(	(
BA	NP	BA
)	)	)
and	CC	and
coronary	JJ	coronary
heart	NN	heart
disease	NN	disease
(	(	(
CHD	NP	<unknown>
)	)	)
,	,	,
is	VBZ	be
a	DT	a
relevant	JJ	relevant
issue	NN	issue
of	IN	of
modern	JJ	modern
therapy	NN	therapy
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
the	DT	the
research	NN	research
is	VBZ	be
to	TO	to
study	VV	study
the	DT	the
impact	NN	impact
of	IN	of
long-term	JJ	long-term
intake	NN	intake
of	IN	of
pioglitazone	NN	<unknown>
on	IN	on
the	DT	the
development	NN	development
of	IN	of
inflammation	NN	inflammation
and	CC	and
ED	NN	editor
in	IN	in
patients	NNS	patient
with	IN	with
BA	NP	BA
concurrent	NN	concurrent
with	IN	with
CHD.The	JJ	<unknown>
clinical	JJ	clinical
study	NN	study
involved	VVD	involve
50	CD	@card@
people	NNS	people
aged	JJ	aged
40-75	CD	@card@
who	WP	who
suffered	VVD	suffer
from	IN	from
asthma	NN	asthma
concurrent	JJ	concurrent
with	IN	with
CHD	NP	<unknown>
.	SENT	.
On	IN	on
the	DT	the
first	JJ	first
day	NN	day
of	IN	of
the	DT	the
study	NN	study
,	,	,
blood	NN	blood
samples	NNS	sample
were	VBD	be
collected	VVN	collect
and	CC	and
clinical	JJ	clinical
examinations	NNS	examination
were	VBD	be
performed	VVN	perform
,	,	,
after	IN	after
which	WDT	which
patients	NNS	patient
were	VBD	be
randomized	VVN	randomize
and	CC	and
divided	VVN	divide
into	IN	into
the	DT	the
control	NN	control
group	NN	group
who	WP	who
continued	VVD	continue
to	TO	to
receive	VV	receive
only	RB	only
the	DT	the
standard	JJ	standard
therapy	NN	therapy
,	,	,
and	CC	and
the	DT	the
study	NN	study
group	NN	group
,	,	,
who	WP	who
received	VVD	receive
pioglitazone	NN	<unknown>
(	(	(
Pioglar	NP	<unknown>
,	,	,
Ranbaxy	NP	<unknown>
,	,	,
India	NP	India
)	)	)
15	CD	@card@
mg	NN	mg
once	IN	once
a	DT	a
day	NN	day
along	IN	along
with	IN	with
comprehensive	JJ	comprehensive
therapy	NN	therapy
.	SENT	.
Re-examination	NN	re-examination
was	VBD	be
carried	VVN	carry
out	RP	out
in	IN	in
6	CD	@card@
months.It	NN	<unknown>
has	VHZ	have
been	VBN	be
found	VVN	find
that	DT	that
inclusion	NN	inclusion
of	IN	of
pioglitazone	NN	<unknown>
in	IN	in
the	DT	the
course	NN	course
of	IN	of
standard	JJ	standard
therapy	NN	therapy
in	IN	in
patients	NNS	patient
with	IN	with
asthma	NN	asthma
concurrent	JJ	concurrent
with	IN	with
coronary	JJ	coronary
heart	NN	heart
within	IN	within
6	CD	@card@
months	NNS	month
is	VBZ	be
a	DT	a
more	RBR	more
efficient	JJ	efficient
scheme	NN	scheme
than	IN	than
the	DT	the
course	NN	course
of	IN	of
standard	JJ	standard
therapies	NNS	therapy
.	SENT	.
According	VVG	accord
to	TO	to
the	DT	the
data	NNS	datum
obtained	VVN	obtain
from	IN	from
the	DT	the
patients	NNS	patient
,	,	,
there	EX	there
was	VBD	be
a	DT	a
significant	JJ	significant
decrease	NN	decrease
in	IN	in
respiratory	JJ	respiratory
rate	NN	rate
(	(	(
p&lt	VV	<unknown>
;	:	;
0.01	LS	@card@
)	)	)
,	,	,
levels	NNS	level
of	IN	of
systolic	JJ	systolic
blood	NN	blood
pressure	NN	pressure
(	(	(
p&lt	VV	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
diastolic	JJ	diastolic
blood	NN	blood
pressure	NN	pressure
(	(	(
p&lt	VV	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Administering	VVG	administer
pioglitazone	NN	<unknown>
contributed	VVD	contribute
to	TO	to
the	DT	the
improvement	NN	improvement
of	IN	of
respiratory	JJ	respiratory
function	NN	function
and	CC	and
airflow	NN	airflow
obstruction	NN	obstruction
,	,	,
increased	VVD	increase
FEV1	JJ	<unknown>
performance	NN	performance
(	(	(
p&lt	VV	<unknown>
;	:	;
0.01	LS	@card@
)	)	)
and	CC	and
Tiffeneau	NP	<unknown>
index	NN	index
(	(	(
p&lt	VV	<unknown>
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
In	IN	in
patients	NNS	patient
of	IN	of
the	DT	the
study	NN	study
group	NN	group
,	,	,
intake	NN	intake
of	IN	of
pioglitazone	NN	<unknown>
helped	VVD	help
to	TO	to
reduce	VV	reduce
angina	NN	angina
.	SENT	.
Intake	NN	intake
of	IN	of
pioglitazone	NN	<unknown>
showed	VVD	show
a	DT	a
significant	JJ	significant
decrease	NN	decrease
in	IN	in
the	DT	the
frequency	NN	frequency
of	IN	of
angina	NN	angina
pectoris	NN	pectoris
FC	NP	FC
II	NP	II
(	(	(
p&lt	NP	<unknown>
;	:	;
0.05	LS	@card@
)	)	)
and	CC	and
a	DT	a
significant	JJ	significant
increase	NN	increase
in	IN	in
the	DT	the
frequency	NN	frequency
of	IN	of
angina	NN	angina
FC	NP	FC
I	NP	I
(	(	(
p&lt	NP	<unknown>
;	:	;
0.05	LS	@card@
)	)	)
,	,	,
increase	NN	increase
in	IN	in
the	DT	the
rate	NN	rate
of	IN	of
threshold	NN	threshold
load	NN	load
power	NN	power
(	(	(
p&lt	VV	<unknown>
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
In	IN	in
assessing	VVG	assess
endothelium-dependent	JJ	<unknown>
vasodilation	NN	<unknown>
of	IN	of
the	DT	the
brachial	JJ	brachial
artery	NN	artery
,	,	,
it	PP	it
has	VHZ	have
been	VBN	be
noted	VVN	note
that	DT	that
intake	NN	intake
of	IN	of
pioglitazone	NN	<unknown>
by	IN	by
patients	NNS	patient
with	IN	with
asthma	NN	asthma
concurrent	JJ	concurrent
with	IN	with
coronary	JJ	coronary
heart	NN	heart
disease	NN	disease
resulted	VVN	result
in	IN	in
a	DT	a
statistically	RB	statistically
significant	JJ	significant
increase	NN	increase
in	IN	in
the	DT	the
diameter	NN	diameter
of	IN	of
the	DT	the
brachial	JJ	brachial
artery	NN	artery
by	IN	by
an	DT	an
average	NN	average
of	IN	of
4	CD	@card@
%	NN	%
(	(	(
p&lt	VV	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
,	,	,
the	DT	the
maximum	JJ	maximum
blood	NN	blood
flow	NN	flow
velocity	NN	velocity
(	(	(
TAMX	NP	<unknown>
)	)	)
by	IN	by
an	DT	an
average	NN	average
of	IN	of
40	CD	@card@
%	NN	%
(	(	(
p&lt	VV	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
,	,	,
Δ	JJ	<unknown>
%	NN	%
diameter	NN	diameter
increase	NN	increase
in	IN	in
the	DT	the
brachial	JJ	brachial
artery	NN	artery
(	(	(
p&lt	VV	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
,	,	,
and	CC	and
achieved	VVD	achieve
positive	JJ	positive
indicators	NNS	indicator
of	IN	of
RI	NP	RI
(	(	(
p&lt	NP	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
.	SENT	.
In	IN	in
assessing	VVG	assess
endothelium-dependent	JJ	<unknown>
vasodilation	NN	<unknown>
of	IN	of
brachial	JJ	brachial
artery	NN	artery
in	IN	in
patients	NNS	patient
treated	VVN	treat
with	IN	with
pioglitazone	NN	<unknown>
,	,	,
there	EX	there
was	VBD	be
a	DT	a
significant	JJ	significant
increase	NN	increase
in	IN	in
the	DT	the
diameter	NN	diameter
of	IN	of
brachial	JJ	brachial
artery	NN	artery
on	IN	on
average	NN	average
by	IN	by
5	CD	@card@
%	NN	%
(	(	(
p&lt	VV	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
after	IN	after
taking	VVG	take
nitroglycerin	NN	nitroglycerin
,	,	,
an	DT	an
increase	NN	increase
in	IN	in
?	SENT	?
%	NN	%
diameter	NN	diameter
of	IN	of
brachial	JJ	brachial
artery	NN	artery
(	(	(
p&lt	VV	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
and	CC	and
RI	NP	RI
(	(	(
p&lt	NP	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
.	SENT	.
Inclusion	NN	inclusion
of	IN	of
pioglitazone	NN	<unknown>
in	IN	in
the	DT	the
complex	JJ	complex
therapy	NN	therapy
for	IN	for
6	CD	@card@
months	NNS	month
resulted	VVN	result
in	IN	in
a	DT	a
significant	JJ	significant
decrease	NN	decrease
in	IN	in
the	DT	the
index	NN	index
of	IN	of
systemic	JJ	systemic
inflammation	NN	inflammation
hs-CRP	NP	<unknown>
(	(	(
p&lt	NP	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
and	CC	and
adhesion	NN	adhesion
marker	NN	marker
sVCAM-1	NN	<unknown>
(	(	(
p&lt	VV	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
,	,	,
total	JJ	total
cholesterol	NN	cholesterol
(	(	(
p&lt	VV	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
triglycerides	NNS	triglyceride
(	(	(
p&lt	NP	<unknown>
;	:	;
0.001).Thus	NN	<unknown>
,	,	,
these	DT	these
data	NNS	datum
demonstrate	VVP	demonstrate
the	DT	the
anti-inflammatory	JJ	anti-inflammatory
and	CC	and
endothelium	NN	endothelium
protective	JJ	protective
effects	NNS	effect
of	IN	of
pioglitazone	NN	<unknown>
against	IN	against
the	DT	the
background	NN	background
of	IN	of
standard	JJ	standard
therapy	NN	therapy
in	IN	in
patients	NNS	patient
with	IN	with
BA	NP	BA
concurrent	NN	concurrent
with	IN	with
CHD	NN	<unknown>
within	IN	within
6	CD	@card@
months	NNS	month
,	,	,
which	WDT	which
may	MD	may
enhance	VV	enhance
the	DT	the
clinical	JJ	clinical
efficacy	NN	efficacy
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
these	DT	these
diseases	NNS	disease
.	SENT	.
T.	NP	T.
The	NP	The
Micronome	NP	<unknown>
of	IN	of
Mesenchymal	NP	<unknown>
Stromal	NP	<unknown>
Cells	NP	<unknown>
is	VBZ	be
partially	RB	partially
responsive	JJ	responsive
to	TO	to
Inflammation	NN	inflammation
.	SENT	.
A.	NP	A.
Mesenchymal	NP	<unknown>
stromal	JJ	<unknown>
cells	NNS	cell
(	(	(
MSCs	NP	<unknown>
)	)	)
display	VVP	display
a	DT	a
special	JJ	special
immunological	JJ	immunological
profile	NN	profile
that	WDT	that
allows	VVZ	allow
their	PP$	their
potential	JJ	potential
use	NN	use
as	IN	as
immunotherapeutic	JJ	<unknown>
cells	NNS	cell
.	SENT	.
Nowadays	RB	nowadays
,	,	,
Foreskin	NP	<unknown>
(	(	(
FSK	NP	<unknown>
)	)	)
represents	VVZ	represent
a	DT	a
valuable	JJ	valuable
reservoir	NN	reservoir
of	IN	of
MSCs	NP	<unknown>
with	IN	with
International	NP	International
Society	NP	Society
for	IN	for
cellular	JJ	cellular
Therapy	NN	therapy
(	(	(
ISCT	JJ	<unknown>
)	)	)
compliant	JJ	compliant
criteria	NNS	criterion
and	CC	and
relevant	JJ	relevant
functional	JJ	functional
properties	NNS	property
.	SENT	.
However	RB	however
,	,	,
their	PP$	their
mode	NN	mode
of	IN	of
action	NN	action
is	VBZ	be
poorly	RB	poorly
understood	VVN	understand
and	CC	and
needs	VVZ	need
to	TO	to
be	VB	be
more	RBR	more
elucidated	VVN	elucidate
to	TO	to
optimize	VV	optimize
their	PP$	their
therapeutic	JJ	therapeutic
use	NN	use
.	SENT	.
Because	IN	because
microRNAs	NNS	<unknown>
(	(	(
miRNAs	NNS	<unknown>
)	)	)
act	VVP	act
as	IN	as
key	JJ	key
regulators	NNS	regulator
in	IN	in
a	DT	a
wide	JJ	wide
variety	NN	variety
of	IN	of
biological	JJ	biological
processes	NNS	process
,	,	,
we	PP	we
decided	VVD	decide
to	TO	to
establish	VV	establish
the	DT	the
micronome	NN	<unknown>
of	IN	of
FSK-MSCs	NP	<unknown>
,	,	,
the	DT	the
influence	NN	influence
of	IN	of
inflammation	NN	inflammation
and	CC	and
the	DT	the
predicted	VVN	predict
target	NN	target
pathways	NNS	pathway
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
provide	VVP	provide
the	DT	the
full	JJ	full
list	NN	list
of	IN	of
unchanged	JJ	unchanged
and	CC	and
additional	JJ	additional
four	CD	four
differentially	RB	differentially
expressed	VVN	express
miRNAs	NNS	<unknown>
,	,	,
miR-199b	NN	<unknown>
,	,	,
-296-3p	NN	<unknown>
and	CC	and
-589-5p	NN	<unknown>
being	VBG	be
downregulated	VVN	<unknown>
whilst	IN	whilst
miR-146-3p	NN	<unknown>
being	VBG	be
upregulated	VVN	<unknown>
,	,	,
in	IN	in
MSCs	NP	<unknown>
following	VVG	follow
their	PP$	their
exposure	NN	exposure
to	TO	to
a	DT	a
cocktail	NN	cocktail
of	IN	of
proinflammatory	JJ	<unknown>
cytokines	NNS	<unknown>
.	SENT	.
MicroRNA	NP	<unknown>
target	NN	target
prediction	NN	prediction
in	IN	in
addition	NN	addition
to	TO	to
Pathway	NP	<unknown>
enrichment	NN	enrichment
analysis	NN	analysis
performed	VVD	perform
using	VVG	use
miRNet	NN	<unknown>
,	,	,
showed	VVD	show
that	IN/that	that
miR-296-3p	NN	<unknown>
is	VBZ	be
linked	VVN	link
to	TO	to
antigen	NN	antigen
processing	NN	processing
and	CC	and
presentation	NN	presentation
pathway	NN	pathway
.	SENT	.
Collectively	RB	collectively
,	,	,
our	PP$	our
data	NN	data
indicates	VVZ	indicate
that	IN/that	that
the	DT	the
micronome	NN	<unknown>
of	IN	of
FSK-MSCs	NP	<unknown>
is	VBZ	be
partially	RB	partially
responsive	JJ	responsive
to	TO	to
inflammation	NN	inflammation
.	SENT	.
Differentially	RB	differentially
expressed	VVN	express
miRNAs	NNS	<unknown>
are	VBP	be
subsequently	RB	subsequently
modulated	VVN	modulate
by	IN	by
inflammation	NN	inflammation
and	CC	and
seems	VVZ	seem
to	TO	to
be	VB	be
involved	VVN	involve
in	IN	in
regulating	VVG	regulate
the	DT	the
immunological	JJ	immunological
fate	NN	fate
of	IN	of
FSK-MSCs	NP	<unknown>
.	SENT	.
These	DT	these
miRNAs	NNS	<unknown>
deserve	VVP	deserve
more	JJR	more
attention	NN	attention
in	IN	in
order	NN	order
to	TO	to
optimize	VV	optimize
MSC-based	JJ	<unknown>
therapy	NN	therapy
and	CC	and
achieve	VV	achieve
the	DT	the
appropriate	JJ	appropriate
therapeutic	JJ	therapeutic
effect	NN	effect
.	SENT	.
T.	NP	T.
Changes	NP	Changes
of	IN	of
Metabolic	NP	<unknown>
Disorders	NP	<unknown>
Associated	NP	Associated
Peripheral	NP	<unknown>
Cytokine/Adipokine	NP	<unknown>
Traffic	NP	Traffic
in	IN	in
Non-Obese	NP	<unknown>
Chronic	NP	<unknown>
Back	NP	Back
Patients	NPS	Patients
Responsive	NP	<unknown>
to	TO	to
Burst	NP	<unknown>
Spinal	NP	<unknown>
Cord	NP	Cord
Stimulation	NP	<unknown>
.	SENT	.
A.	NP	A.
In	IN	in
our	PP$	our
previous	JJ	previous
study	NN	study
,	,	,
anti-inflammatory	JJ	anti-inflammatory
IL-10	NP	<unknown>
serum	NN	serum
levels	NNS	level
were	VBD	be
significantly	RB	significantly
elevated	VVN	elevate
after	IN	after
burst	NN	burst
spinal	JJ	spinal
cord	NN	cord
stimulation	NN	stimulation
(	(	(
SCS	NP	<unknown>
)	)	)
in	IN	in
back	JJ	back
pain	NN	pain
patients	NNS	patient
and	CC	and
correlated	VVN	correlate
with	IN	with
pain	NN	pain
intensity	NN	intensity
.	SENT	.
This	DT	this
current	JJ	current
study	NN	study
extended	VVD	extend
cytokine	JJ	<unknown>
analysis	NN	analysis
including	VVG	include
metabolic-associated	JJ	<unknown>
adipokine/cytokine	NN	<unknown>
serum	NN	serum
assessment	NN	assessment
in	IN	in
chronic	JJ	chronic
back	JJ	back
pain	NN	pain
patients	NNS	patient
with	IN	with
co-existing	VVG	<unknown>
metabolic	JJ	metabolic
disorders	NNS	disorder
such	JJ	such
as	IN	as
diabetes	NN	diabetes
,	,	,
hypertension	NN	hypertension
,	,	,
and	CC	and
cardiovascular	JJ	cardiovascular
diseases.At	NN	<unknown>
baseline	NN	baseline
and	CC	and
after	IN	after
three	CD	three
months	NNS	month
of	IN	of
burst	NN	burst
SCS	NP	<unknown>
treatment	NN	treatment
,	,	,
leptin	NN	<unknown>
(	(	(
LP	NP	LP
)	)	)
,	,	,
adiponectin	NN	<unknown>
(	(	(
AN	DT	an
)	)	)
,	,	,
and	CC	and
ghrelin	NP	<unknown>
(	(	(
GH	NP	GH
)	)	)
were	VBD	be
recorded	VVN	record
in	IN	in
non-/pre-obese	JJ	<unknown>
chronic	JJ	chronic
back	JJ	back
pain	NN	pain
patients	NNS	patient
with	IN	with
co-existing	VVG	<unknown>
metabolic	JJ	metabolic
disorders	NNS	disorder
and	CC	and
compared	VVN	compare
to	TO	to
age-/gender-matched	JJ	<unknown>
healthy	JJ	healthy
controls	NNS	control
(	(	(
HC).Mean	NP	<unknown>
BMI	NP	BMI
was	VBD	be
22 ± 0.81	JJ	<unknown>
kg/m(2	NN	<unknown>
)	)	)
in	IN	in
12	CD	@card@
(	(	(
five	CD	five
male/seven	NN	<unknown>
female	JJ	female
)	)	)
participants	NNS	participant
with	IN	with
diabetes	NN	diabetes
in	IN	in
6/12	CD	@card@
(	(	(
50	CD	@card@
%	NN	%
)	)	)
,	,	,
hypertension	NN	hypertension
in	IN	in
9	CD	@card@
(	(	(
75	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
CVD	NN	<unknown>
in	IN	in
five	CD	five
patients	NNS	patient
(	(	(
42	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Pre-	NN	pre-
and	CC	and
post-SCS	NP	<unknown>
LP	NP	LP
levels	NNS	level
were	VBD	be
significantly	RB	significantly
higher	RBR	higher
compared	VVN	compare
to	TO	to
healthy	JJ	healthy
controls	NNS	control
:	:	:
pre-SCS	NNS	<unknown>
,	,	,
30567	CD	@card@
(	(	(
12,996-58,821	CD	@card@
)	)	)
vs.	IN	vs.
HC	NP	<unknown>
,	,	,
7952	CD	@card@
(	(	(
4932-12,583	CD	@card@
)	)	)
pg/mL	NN	<unknown>
,	,	,
p = 0.029	NN	<unknown>
;	:	;
post-SCS	NP	<unknown>
,	,	,
18,890	CD	@card@
(	(	(
7140-44,719	CD	@card@
)	)	)
vs.	IN	vs.
HC	NP	<unknown>
,	,	,
7952	CD	@card@
(	(	(
4932-12,583	CD	@card@
)	)	)
pg/mL	NN	<unknown>
,	,	,
p = 0.035	NN	<unknown>
.	SENT	.
Pre-	NN	pre-
and	CC	and
post-SCS	NN	<unknown>
changes	NNS	change
of	IN	of
GH	NP	GH
(	(	(
p = 0.18	NN	<unknown>
)	)	)
and	CC	and
AN	DT	an
(	(	(
p = 0.8	NN	<unknown>
)	)	)
did	VVD	do
not	RB	not
differ	VV	differ
significantly	RB	significantly
.	SENT	.
GH	NP	GH
serum	NN	serum
levels	NNS	level
correlated	VVN	correlate
with	IN	with
AN	DT	an
(	(	(
Spearman	NP	Spearman
r = 0.5	NN	<unknown>
;	:	;
p = 0.012	NN	<unknown>
;	:	;
95	CD	@card@
CI	NN	<unknown>
0.11	CD	@card@
to	TO	to
-0.76	CD	@card@
)	)	)
and	CC	and
AN	DT	an
levels	NNS	level
were	VBD	be
significantly	RB	significantly
correlated	VVN	correlate
with	IN	with
higher	JJR	high
age	NN	age
(	(	(
Pearson	NP	Pearson
correlation	NN	correlation
r = 0.8	NN	<unknown>
;	:	;
p = 0.002	NN	<unknown>
;	:	;
95	CD	@card@
CI	NP	<unknown>
0.41-0.94	CD	@card@
)	)	)
at	IN	at
baseline.This	NN	<unknown>
study	NN	study
determined	VVD	determine
serum	NN	serum
changes	NNS	change
of	IN	of
metabolic-associated	JJ	<unknown>
cytokines/adipokines	NNS	<unknown>
in	IN	in
non-obese	JJ	<unknown>
chronic	JJ	chronic
back	JJ	back
pain	NN	pain
patients	NNS	patient
responsive	JJ	responsive
to	TO	to
burst	VV	burst
SCS	NP	<unknown>
suggesting	VVG	suggest
that	DT	that
neuroinflammation	NN	<unknown>
assessment	NN	assessment
may	MD	may
consider	VV	consider
pain-associated	JJ	<unknown>
mood	NN	mood
,	,	,
cognition	NN	cognition
,	,	,
sleep	NN	sleep
,	,	,
and	CC	and
metabolic	JJ	metabolic
state	NN	state
.	SENT	.
T.	NP	T.
Spinal	NP	<unknown>
Cord	NP	Cord
Stimulation	NP	<unknown>
in	IN	in
Patients	NPS	Patients
With	IN	with
Complex	NP	<unknown>
Regional	NP	Regional
Pain	NP	Pain
Syndrome	NP	<unknown>
:	:	:
A	DT	a
Possible	JJ	possible
Target	NP	Target
for	IN	for
Immunomodulation	NP	<unknown>
?	SENT	?
A.	NP	A.
Complex	NP	<unknown>
regional	JJ	regional
pain	NN	pain
syndrome	NN	syndrome
(	(	(
CRPS	NP	<unknown>
)	)	)
is	VBZ	be
characterized	VVN	characterize
by	IN	by
continued	JJ	continued
pain	NN	pain
disproportional	JJ	<unknown>
to	TO	to
the	DT	the
inciting	VVG	incite
event	NN	event
,	,	,
sensory	JJ	sensory
abnormalities	NNS	abnormality
,	,	,
vasomotor	JJ	vasomotor
and	CC	and
sudomotor	NN	<unknown>
disturbances	NNS	disturbance
,	,	,
and	CC	and
motor	NN	motor
and	CC	and
trophic	JJ	trophic
changes	NNS	change
.	SENT	.
Inflammatory	JJ	inflammatory
involvement	NN	involvement
has	VHZ	have
been	VBN	be
demonstrated	VVN	demonstrate
in	IN	in
past	JJ	past
CRPS	NP	<unknown>
studies	NNS	study
resulting	VVG	result
in	IN	in
pain	NN	pain
,	,	,
swelling	VVG	swell
,	,	,
and	CC	and
warmth	NN	warmth
.	SENT	.
Currently	RB	currently
,	,	,
it	PP	it
is	VBZ	be
unknown	JJ	unknown
whether	IN	whether
spinal	JJ	spinal
cord	NN	cord
stimulation	NN	stimulation
(	(	(
SCS	NP	<unknown>
)	)	)
has	VHZ	have
immunomodulatory	JJ	<unknown>
properties	NNS	property
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
determine	VV	determine
whether	IN	whether
SCS	NP	<unknown>
has	VHZ	have
immunomodulatory	JJ	<unknown>
properties	NNS	property
in	IN	in
CRPS	NP	<unknown>
patients.The	JJ	<unknown>
primary	JJ	primary
outcome	NN	outcome
parameters	NNS	parameter
are	VBP	be
cytokines	NNS	<unknown>
(	(	(
IL-2	NP	<unknown>
,	,	,
IL-4	NN	IL-4
,	,	,
IL-5	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
IL-10	NP	<unknown>
,	,	,
IL-12	NP	<unknown>
,	,	,
IL-13	NP	<unknown>
,	,	,
IL-15	NP	<unknown>
,	,	,
IL-17	NP	<unknown>
,	,	,
TNF-α	NP	<unknown>
,	,	,
IFN-γ	NP	<unknown>
)	)	)
,	,	,
chemokines	NNS	<unknown>
(	(	(
IP-10	NP	<unknown>
and	CC	and
Eotaxin	NP	<unknown>
)	)	)
,	,	,
and	CC	and
growth	NN	growth
factors	NNS	factor
(	(	(
VEGF	NP	<unknown>
,	,	,
PDGFbb	NP	<unknown>
,	,	,
and	CC	and
basic	JJ	basic
FGF	NN	<unknown>
)	)	)
from	IN	from
interstitial	JJ	interstitial
fluid	NN	fluid
of	IN	of
artificial	JJ	artificial
skin	NN	skin
blisters	NNS	blister
before	IN	before
(	(	(
T0-baseline	NP	<unknown>
without	IN	without
SCS	NP	<unknown>
)	)	)
and	CC	and
after	IN	after
SCS	NP	<unknown>
therapy	NN	therapy
(	(	(
T1-40	NP	<unknown>
Hz	NP	hz
standard	JJ	standard
frequency	NN	frequency
stimulation	NN	stimulation
and	CC	and
T2-preferred	JJ	<unknown>
frequency	NN	frequency
stimulation	NN	stimulation
)	)	)
.	SENT	.
Secondary	JJ	secondary
outcome	NN	outcome
parameters	NNS	parameter
were	VBD	be
baseline	JJ	baseline
demographics	NNS	demographic
,	,	,
CRPS	NP	<unknown>
signs	NNS	sign
,	,	,
symptoms	NNS	symptom
,	,	,
and	CC	and
phenotype	NN	phenotype
(	(	(
inflammatory	JJ	inflammatory
,	,	,
vasomotor	JJ	vasomotor
,	,	,
dystonia	NN	<unknown>
,	,	,
or	CC	or
neuropathic	JJ	neuropathic
)	)	)
.	SENT	.
Results	NNS	result
were	VBD	be
analyzed	VVN	analyze
by	IN	by
means	NNS	mean
of	IN	of
a	DT	a
MANOVA	NP	<unknown>
repeated	VVD	repeat
measures	NNS	measure
design.After	NP	<unknown>
SCS	NP	<unknown>
,	,	,
the	DT	the
expression	NN	expression
of	IN	of
both	DT	both
pro-	NN	pro-
and	CC	and
anti-inflammatory	JJ	anti-inflammatory
cytokines	NNS	<unknown>
decreased	VVN	decrease
over	IN	over
time	NN	time
in	IN	in
both	CC	both
the	DT	the
CRPS	NP	<unknown>
affected	JJ	affected
extremity	NN	extremity
and	CC	and
the	DT	the
contralateral	JJ	<unknown>
extremity	NN	extremity
.	SENT	.
The	DT	the
levels	NNS	level
of	IN	of
IP-10	NP	<unknown>
,	,	,
Eotaxin	NP	<unknown>
,	,	,
VEGF	NP	<unknown>
,	,	,
and	CC	and
PDGFbb	NP	<unknown>
were	VBD	be
also	RB	also
significantly	RB	significantly
reduced	VVN	reduce
bilaterally	RB	bilaterally
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
significant	JJ	significant
changes	NNS	change
in	IN	in
IL-6	NP	<unknown>
and	CC	and
TNF-α	NP	<unknown>
before	IN	before
and	CC	and
after	IN	after
SCS	NP	<unknown>
.	SENT	.
The	DT	the
sensory	JJ	sensory
signs	NNS	sign
,	,	,
symptoms	NNS	symptom
,	,	,
and	CC	and
phenotype	NN	phenotype
improved	VVN	improve
after	IN	after
SCS.SCS	NP	<unknown>
in	IN	in
CRPS	NP	<unknown>
patients	NNS	patient
attenuates	VVZ	attenuate
T-cell	NN	T-cell
activation	NN	activation
,	,	,
improves	VVZ	improve
peripheral	JJ	peripheral
tissue	NN	tissue
oxygenation	NN	oxygenation
and	CC	and
decreases	VVZ	decrease
anti-angiogenetic	JJ	<unknown>
activity	NN	activity
which	WDT	which
results	VVZ	result
in	IN	in
diminished	JJ	diminished
endothelial	JJ	endothelial
dysfunction	NN	dysfunction
and	CC	and
improved	VVN	improve
bloodflow	NN	<unknown>
.	SENT	.
The	DT	the
possible	JJ	possible
immunomodulatory	JJ	<unknown>
effects	NNS	effect
of	IN	of
SCS	NP	<unknown>
opens	VVZ	open
new	JJ	new
therapeutic	JJ	therapeutic
possibilities	NNS	possibility
in	IN	in
diseases	NNS	disease
with	IN	with
the	DT	the
involvement	NN	involvement
of	IN	of
the	DT	the
immune	JJ	immune
system	NN	system
and	CC	and
vasomotor	JJ	vasomotor
disturbances	NNS	disturbance
,	,	,
and	CC	and
requires	VVZ	require
further	JJR	further
research	NN	research
on	IN	on
these	DT	these
mechanisms	NNS	mechanism
of	IN	of
action	NN	action
.	SENT	.
T.	NP	T.
Elevated	NP	<unknown>
leukocyte	NN	<unknown>
count	NN	count
as	IN	as
a	DT	a
harbinger	NN	harbinger
of	IN	of
systemic	JJ	systemic
inflammation	NN	inflammation
,	,	,
disease	NN	disease
progression	NN	progression
,	,	,
and	CC	and
poor	JJ	poor
prognosis	NN	prognosis
:	:	:
a	DT	a
review	NN	review
.	SENT	.
A.	NP	A.
Total	NP	Total
leukocyte	NN	<unknown>
count	NN	count
increases	VVZ	increase
significantly	RB	significantly
in	IN	in
response	NN	response
to	TO	to
infection	NN	infection
,	,	,
trauma	NN	trauma
,	,	,
inflammation	NN	inflammation
,	,	,
and	CC	and
certain	JJ	certain
diseases	NNS	disease
.	SENT	.
Factors	NNS	factor
affecting	VVG	affect
leukocyte	NN	<unknown>
count	NN	count
in	IN	in
healthy	JJ	healthy
adults	NNS	adult
include	VVP	include
sex	NN	sex
,	,	,
hormonal	JJ	hormonal
milieu	NN	milieu
,	,	,
genetic	JJ	genetic
inheritance	NN	inheritance
,	,	,
stress	NN	stress
level	NN	level
,	,	,
diet	NN	diet
,	,	,
nutrition	NN	nutrition
,	,	,
and	CC	and
lifestyle	NN	lifestyle
(	(	(
e.g.	FW	e.g.
tobacco-induced	JJ	<unknown>
inflammatory	JJ	inflammatory
changes	NNS	change
,	,	,
chronic	JJ	chronic
psychological	JJ	psychological
stress	NN	stress
,	,	,
etc.	FW	etc.
)	)	)
.	SENT	.
To	TO	to
date	NN	date
,	,	,
numerous	JJ	numerous
studies	NNS	study
have	VHP	have
reported	VVN	report
that	IN/that	that
high	JJ	high
but	CC	but
normal	JJ	normal
leukocyte	NN	<unknown>
counts	NNS	count
at	IN	at
baseline	NN	baseline
predict	VVP	predict
increased	VVN	increase
cardiovascular	JJ	cardiovascular
and	CC	and
noncardiovascular	JJ	<unknown>
mortality	NN	mortality
in	IN	in
older	JJR	old
adults	NNS	adult
.	SENT	.
Recent	JJ	Recent
findings	NNS	finding
suggest	VVP	suggest
that	IN/that	that
elevated	JJ	elevated
leukocyte	NN	<unknown>
count	NN	count
within	IN	within
the	DT	the
normal	JJ	normal
range	NN	range
,	,	,
but	CC	but
especially	RB	especially
neutrophil	JJ	neutrophil
and	CC	and
monocyte	NN	monocyte
counts	NNS	count
,	,	,
may	MD	may
be	VB	be
a	DT	a
harbinger	NN	harbinger
of	IN	of
increased	VVN	increase
systemic	JJ	systemic
inflammation	NN	inflammation
and	CC	and
subclinical	JJ	subclinical
disease	NN	disease
.	SENT	.
Moreover	RB	moreover
,	,	,
elderly	JJ	elderly
people	NNS	people
who	WP	who
tend	VVP	tend
to	TO	to
have	VH	have
high	JJ	high
but	CC	but
normal	JJ	normal
leukocyte	NN	<unknown>
counts	NNS	count
are	VBP	be
at	IN	at
greater	JJR	great
risk	NN	risk
of	IN	of
cancer	NN	cancer
,	,	,
cardiovascular	JJ	cardiovascular
disease	NN	disease
,	,	,
type	NN	type
2	CD	@card@
diabetes	NN	diabetes
,	,	,
some	DT	some
other	JJ	other
age-related	JJ	age-related
conditions	NNS	condition
,	,	,
and	CC	and
they	PP	they
also	RB	also
have	VHP	have
increased	VVN	increase
all-cause	JJ	<unknown>
mortality	NN	mortality
.	SENT	.
These	DT	these
results	NNS	result
indicate	VVP	indicate
that	IN/that	that
strong	JJ	strong
and	CC	and
reliable	JJ	reliable
inflammatory	JJ	inflammatory
markers	NNS	marker
,	,	,
such	JJ	such
as	IN	as
leukocyte	NN	<unknown>
count	NN	count
,	,	,
may	MD	may
reflect	VV	reflect
the	DT	the
rate	NN	rate
of	IN	of
ageing	VVG	age
and	CC	and
therefore	RB	therefore
can	MD	can
predict	VV	predict
long-term	JJ	long-term
survival	NN	survival
in	IN	in
the	DT	the
elderly	JJ	elderly
.	SENT	.
Remarkably	RB	remarkably
,	,	,
leukocyte	NN	<unknown>
count	NN	count
correlates	VVZ	correlate
positively	RB	positively
with	IN	with
genuine	JJ	genuine
markers	NNS	marker
of	IN	of
systemic	JJ	systemic
inflammation	NN	inflammation
like	IN	like
C-reactive	JJ	<unknown>
protein	NN	protein
and	CC	and
interleukin	NN	interleukin
6.	CD	@ord@
Interestingly	NN	<unknown>
,	,	,
some	DT	some
authors	NNS	author
conclude	VVP	conclude
that	IN/that	that
leukocyte	NN	<unknown>
counts	NNS	count
have	VHP	have
a	DT	a
stronger	JJR	strong
prognostic	JJ	prognostic
ability	NN	ability
with	IN	with
regard	NN	regard
to	TO	to
total	JJ	total
and	CC	and
cardiovascular	JJ	cardiovascular
mortality	NN	mortality
than	IN	than
total	JJ	total
cholesterol	NN	cholesterol
or	CC	or
low-density	NN	low-density
lipoproteins	NNS	lipoprotein
.	SENT	.
The	DT	the
fact	NN	fact
that	IN/that	that
these	DT	these
inflammatory	JJ	inflammatory
markers	NNS	marker
are	VBP	be
clinically	RB	clinically
useful	JJ	useful
predictors	NNS	predictor
of	IN	of
long-term	JJ	long-term
survival	NN	survival
in	IN	in
the	DT	the
elderly	JJ	elderly
is	VBZ	be
quite	RB	quite
remarkable	JJ	remarkable
as	IN	as
these	DT	these
blood	NN	blood
parameters	NNS	parameter
are	VBP	be
included	VVN	include
in	IN	in
routine	JJ	routine
medical	JJ	medical
check-ups	NNS	check-up
.	SENT	.
Therefore	RB	therefore
,	,	,
they	PP	they
can	MD	can
be	VB	be
used	VVN	use
as	IN	as
simple	JJ	simple
and	CC	and
reliable	JJ	reliable
morphological	JJ	morphological
indicators	NNS	indicator
of	IN	of
chronic	JJ	chronic
systemic	JJ	systemic
inflammation	NN	inflammation
,	,	,
disease	NN	disease
progression	NN	progression
,	,	,
and	CC	and
poor	JJ	poor
prognosis	NN	prognosis
,	,	,
especially	RB	especially
among	IN	among
individuals	NNS	individual
who	WP	who
are	VBP	be
likely	JJ	likely
to	TO	to
develop	VV	develop
age-related	JJ	age-related
conditions	NNS	condition
.	SENT	.
Nevertheless	RB	nevertheless
,	,	,
the	DT	the
pathomechanism	NN	<unknown>
that	WDT	that
links	VVZ	link
elevated	JJ	elevated
but	CC	but
normal	JJ	normal
leukocyte	NN	<unknown>
counts	VVZ	count
to	TO	to
increased	VVN	increase
mortality	NN	mortality
remains	VVZ	remain
poorly	RB	poorly
understood	VVN	understand
.	SENT	.
This	DT	this
review	NN	review
summarises	VVZ	summarise
the	DT	the
most	RBS	most
important	JJ	important
findings	NNS	finding
on	IN	on
the	DT	the
links	NNS	link
between	IN	between
leukocyte	NN	<unknown>
count	NN	count
,	,	,
chronic	JJ	chronic
systemic	JJ	systemic
inflammation	NN	inflammation
,	,	,
and	CC	and
health	NN	health
outcomes	NNS	outcome
in	IN	in
older	JJR	old
adults	NNS	adult
.	SENT	.
T.	NP	T.
In-stent	NP	<unknown>
restenosis-prone	NP	<unknown>
coronary	JJ	coronary
plaque	NN	plaque
composition	NN	composition
:	:	:
A	DT	a
retrospective	JJ	retrospective
virtual	JJ	virtual
histology-intravascular	JJ	<unknown>
ultrasound	NN	ultrasound
study	NN	study
.	SENT	.
A.	NP	A.
The	DT	the
mechanism	NN	mechanism
of	IN	of
in-stent	JJ	<unknown>
restenosis	NN	<unknown>
(	(	(
ISR	NP	<unknown>
)	)	)
is	VBZ	be
multifactorial	JJ	multifactorial
,	,	,
which	WDT	which
includes	VVZ	include
biological	JJ	biological
,	,	,
mechanical	JJ	mechanical
and	CC	and
technical	JJ	technical
factors	NNS	factor
.	SENT	.
This	DT	this
study	NN	study
hypothesized	VVD	hypothesize
that	DT	that
increased	VVN	increase
inflammatory	JJ	inflammatory
reaction	NN	reaction
,	,	,
which	WDT	which
is	VBZ	be
known	VVN	know
to	TO	to
be	VB	be
an	DT	an
important	JJ	important
atherosclerotic	JJ	atherosclerotic
process	NN	process
,	,	,
at	IN	at
a	DT	a
culprit	NN	culprit
lesion	NN	lesion
may	MD	may
lead	VV	lead
to	TO	to
higher	JJR	high
restenosis	NN	<unknown>
rates.The	NN	<unknown>
study	NN	study
population	NN	population
consisted	VVN	consist
of	IN	of
241	CD	@card@
patients	NNS	patient
who	WP	who
had	VHD	have
undergone	VVN	undergo
percutaneous	JJ	percutaneous
coronary	JJ	coronary
intervention	NN	intervention
with	IN	with
virtual	JJ	virtual
histology-intravascular	JJ	<unknown>
ultrasound	NN	ultrasound
(	(	(
VH-IVUS	NP	<unknown>
)	)	)
and	CC	and
a	DT	a
9-month	NN	<unknown>
follow-up	NN	follow-up
coronary	JJ	coronary
angiography	NN	angiography
.	SENT	.
Compared	VVN	compare
herein	RB	herein
is	VBZ	be
the	DT	the
coronary	JJ	coronary
plaque	NN	plaque
composition	NN	composition
between	IN	between
patients	NNS	patient
with	IN	with
ISR	NP	<unknown>
and	CC	and
those	DT	those
without	IN	without
ISR.Patients	NP	<unknown>
with	IN	with
ISR	NP	<unknown>
(	(	(
n	NN	n
=	SYM	=
27	CD	@card@
)	)	)
were	VBD	be
likely	JJ	likely
to	TO	to
be	VB	be
older	JJR	old
(	(	(
66.2	CD	@card@
±	SYM	±
9.5	CD	@card@
years	NNS	year
vs.	IN	vs.
58.7	CD	@card@
±	SYM	±
11.7	CD	@card@
years	NNS	year
,	,	,
p	NN	p
=	SYM	=
0.002	CD	@card@
)	)	)
and	CC	and
have	VH	have
higher	JJR	high
levels	NNS	level
of	IN	of
high-sensitivity	NN	<unknown>
C-reactive	JJ	<unknown>
protein	NN	protein
(	(	(
hs-CRP	NP	<unknown>
,	,	,
1.60	CD	@card@
±	SYM	±
3.59	CD	@card@
mg/dL	NN	<unknown>
vs.	IN	vs.
0.31	CD	@card@
±	SYM	±
0.76	CD	@card@
mg/dL	NN	<unknown>
,	,	,
p	NN	p
&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
than	IN	than
those	DT	those
without	IN	without
ISR	NP	<unknown>
(	(	(
n	NN	n
=	SYM	=
214	CD	@card@
)	)	)
.	SENT	.
VH-IVUS	NP	<unknown>
examination	NN	examination
showed	VVD	show
that	IN/that	that
percent	NN	percent
necrotic	JJ	necrotic
core	NN	core
volume	NN	volume
(	(	(
14.3	CD	@card@
±	SYM	±
8.7	CD	@card@
%	NN	%
vs.	IN	vs.
19.5	CD	@card@
±	SYM	±
9.1	CD	@card@
%	NN	%
,	,	,
p	NN	p
=	SYM	=
0.005	CD	@card@
)	)	)
was	VBD	be
higher	JJR	high
in	IN	in
those	DT	those
without	IN	without
ISR	NP	<unknown>
than	IN	than
those	DT	those
with	IN	with
ISR	NP	<unknown>
.	SENT	.
Multivariate	JJ	multivariate
analysis	NN	analysis
revealed	VVD	reveal
that	IN/that	that
hs-CRP	VVG	<unknown>
(	(	(
odds	NNS	odd
ratio	NN	ratio
[	SYM	[
OR	NP	Or
]	SYM	]
3.334	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
[	SYM	[
CI	NP	<unknown>
]	SYM	]
1.158-9.596	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.026	CD	@card@
)	)	)
and	CC	and
age	NN	age
(	(	(
OR	NP	Or
3.557	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	<unknown>
1.242-10.192	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.018	CD	@card@
)	)	)
were	VBD	be
associated	VVN	associate
with	IN	with
ISR.This	NP	<unknown>
study	NN	study
suggests	VVZ	suggest
that	IN/that	that
ISR	NP	<unknown>
is	VBZ	be
not	RB	not
associated	VVN	associate
with	IN	with
baseline	JJ	baseline
coronary	JJ	coronary
plaque	NN	plaque
composition	NN	composition
but	CC	but
is	VBZ	be
associated	VVN	associate
with	IN	with
old	JJ	old
age	NN	age
and	CC	and
increased	VVN	increase
expression	NN	expression
of	IN	of
the	DT	the
inflammatory	JJ	inflammatory
marker	NN	marker
of	IN	of
hs-CRP	NP	<unknown>
.	SENT	.
T.	NP	T.
Production	NP	Production
and	CC	and
Use	NP	Use
of	IN	of
Hymenolepis	NP	<unknown>
diminuta	NP	<unknown>
Cysticercoids	NP	<unknown>
as	IN	as
Anti-Inflammatory	JJ	anti-inflammatory
Therapeutics	NNS	therapeutics
.	SENT	.
A.	NP	A.
Helminthic	NP	<unknown>
therapy	NN	therapy
has	VHZ	have
shown	VVN	show
considerable	JJ	considerable
promise	NN	promise
as	IN	as
a	DT	a
means	NN	means
of	IN	of
alleviating	VVG	alleviate
some	DT	some
inflammatory	JJ	inflammatory
diseases	NNS	disease
that	WDT	that
have	VHP	have
proven	VVN	prove
resistant	JJ	resistant
to	TO	to
pharmaceutical	JJ	pharmaceutical
intervention	NN	intervention
.	SENT	.
However	RB	however
,	,	,
research	NN	research
in	IN	in
the	DT	the
field	NN	field
has	VHZ	have
been	VBN	be
limited	VVN	limit
by	IN	by
a	DT	a
lack	NN	lack
of	IN	of
availability	NN	availability
to	TO	to
clinician	NN	clinician
scientists	NNS	scientist
of	IN	of
a	DT	a
helminth	NN	helminth
that	WDT	that
is	VBZ	be
relatively	RB	relatively
benign	JJ	benign
,	,	,
non-communicable	JJ	<unknown>
,	,	,
affordable	JJ	affordable
,	,	,
and	CC	and
effectively	RB	effectively
treats	VVZ	treat
disease	NN	disease
.	SENT	.
Previous	JJ	previous
socio-medical	JJ	<unknown>
studies	NNS	study
have	VHP	have
found	VVN	find
that	IN/that	that
some	DT	some
individuals	NNS	individual
self-treating	VVG	<unknown>
with	IN	with
helminths	NNS	helminth
to	TO	to
alleviate	VV	alleviate
various	JJ	various
diseases	NNS	disease
are	VBP	be
using	VVG	use
the	DT	the
rat	NN	rat
tapeworm	NN	tapeworm
(	(	(
cysticercoid	NN	cysticercoid
developmental	JJ	developmental
stage	NN	stage
of	IN	of
Hymenolepis	NP	<unknown>
diminuta	NP	<unknown>
;	:	;
HDC	NP	<unknown>
)	)	)
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
describe	VVP	describe
the	DT	the
production	NN	production
and	CC	and
use	NN	use
of	IN	of
HDCs	NP	<unknown>
in	IN	in
a	DT	a
manner	NN	manner
that	WDT	that
is	VBZ	be
based	VVN	base
on	IN	on
reports	NNS	report
from	IN	from
individuals	NNS	individual
self-treating	VVG	<unknown>
with	IN	with
helminths	NNS	helminth
,	,	,
individuals	NNS	individual
producing	VVG	produce
helminths	NNS	helminth
for	IN	for
self-treatment	NN	self-treatment
,	,	,
and	CC	and
physicians	NNS	physician
monitoring	VVG	monitor
patients	NNS	patient
that	WDT	that
are	VBP	be
self-treating	VVG	<unknown>
.	SENT	.
The	DT	the
helminth	NN	helminth
may	MD	may
fit	VV	fit
the	DT	the
criteria	NNS	criterion
needed	VVN	need
by	IN	by
clinical	JJ	clinical
scientists	NNS	scientist
for	IN	for
clinical	JJ	clinical
trials	NNS	trial
,	,	,
and	CC	and
the	DT	the
methodology	NN	methodology
is	VBZ	be
apparently	RB	apparently
feasible	JJ	feasible
for	IN	for
any	DT	any
medical	JJ	medical
center	NN	center
to	TO	to
reproduce	VV	reproduce
.	SENT	.
It	PP	it
is	VBZ	be
hoped	VVN	hope
that	IN/that	that
future	JJ	future
clinical	JJ	clinical
trials	NNS	trial
using	VVG	use
this	DT	this
organism	NN	organism
may	MD	may
shed	VV	shed
light	NN	light
on	IN	on
the	DT	the
potential	NN	potential
for	IN	for
helminthic	JJ	helminthic
therapy	NN	therapy
to	TO	to
alleviate	VV	alleviate
inflammatory	JJ	inflammatory
diseases	NNS	disease
.	SENT	.
Further	RBR	further
,	,	,
it	PP	it
is	VBZ	be
hoped	VVN	hope
that	IN/that	that
studies	NNS	study
with	IN	with
HDCs	NP	<unknown>
may	MD	may
provide	VV	provide
a	DT	a
stepping	VVG	step
stone	NN	stone
toward	IN	toward
population-wide	JJ	<unknown>
restoration	NN	restoration
of	IN	of
the	DT	the
biota	NN	biota
of	IN	of
the	DT	the
human	JJ	human
body	NN	body
,	,	,
potentially	RB	potentially
reversing	VVG	reverse
the	DT	the
inflammatory	JJ	inflammatory
consequences	NNS	consequence
of	IN	of
biota	NN	biota
depletion	NN	depletion
that	WDT	that
currently	RB	currently
affect	VVP	affect
Western	JJ	Western
society	NN	society
.	SENT	.
